

**TTY BIOPHARM COMPANY LIMITED
AND SUBSIDIARIES**

Consolidated Financial Statements

**With Independent Auditors' Review Report
For the Six Months Ended June 30, 2025 and 2024**

Address: 3F., No. 3-1, Park St., Nangang Dist., Taipei City 115, Taiwan
Telephone: 886-2-26525999

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the consolidated financial statements	8
(3) New standards, amendments and interpretations adopted	8~10
(4) Summary of material accounting policies	10~12
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	12
(6) Explanation of significant accounts	13~43
(7) Related-party transactions	43~45
(8) Assets pledged as security	45
(9) Significant commitments and contingencies	45~46
(10) Losses due to major disasters	46
(11) Subsequent events	46
(12) Other	46~48
(13) Other disclosures	
(a) Information on significant transactions	49~52
(b) Information on investees	52~53
(c) Information on investment in Mainland China	53~54
(14) Segment information	55~56



安侯建業聯合會計師事務所
KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電話 Tel	+ 886 2 8101 6666
傳真 Fax	+ 886 2 8101 6667
網址 Web	kpmg.com/tw

Independent Auditors' Review Report

To the Board of Directors of TTY Biopharm Company Limited:

Introduction

We have reviewed the accompanying consolidated balance sheets of TTY Biopharm Company Limited and its subsidiaries as of June 30, 2025 and 2024, the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months and six months ended June 30, 2025 and 2024 for the six months ended June 30, 2025 and 2024, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the Basis for Qualified Conclusion paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As stated in Note 6(e), the investments accounted for using the equity method of TTY Biopharm Company Limited and its subsidiaries amounting to \$565,008 thousand and \$508,027 thousand as of June 30, 2025 and 2024, respectively, and the related share of profit amounting to \$32,634 thousand, \$20,853 thousand, \$53,503 thousand and \$37,156 thousand for the three months and six months periods ended respectively, were recognized solely on the financial statements prepared by these investee companies, but not reviewed by independent auditors.

Qualified Conclusion

Except for the adjustments, if any, as might have been determined to be necessary had the financial statements of certain equity accounted investee companies described in the Basis for Qualified Conclusion paragraph above been reviewed by independent auditors, based on our reviews and the review report of another auditor (please refer to Other Matter paragraph), nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of TTY Biopharm Company Limited and its subsidiaries as of June 30, 2025 and 2024, and of its consolidated financial performance for the three months and six months ended June 30, 2025 and 2024 and its consolidated cash flows for the six months ended June 30, 2025 and 2024, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Other Matter

We did not review the financial statements of PharmaEngine, Inc., an associate of TTY Biopharm Company Limited and its subsidiaries, which represented as investment accounted for using the equity method. Those financial statements were reviewed by another auditor, whose review report has been furnished to us, and our conclusion, insofar as it relates to the amounts included for PharmaEngine, Inc., is based solely on the review report of another auditor. The investment in PharmaEngine, Inc. accounted for using the equity method amounted to \$1,002,775 thousand and \$864,296 thousand, constituting 9.40% and 8.43% of consolidated total assets as of June 30, 2025 and 2024, respectively, and the related share of profit of associates accounted for using the equity method amounted to \$3,201 thousand, \$28,597 thousand, \$21,616 thousand and \$43,307 thousand, constituting 0.81%, 8.18%, 2.38% and 6.04% of consolidated total profit before tax for the three months and six months ended June 30, 2025 and 2024.

The engagement partners on the reviews resulting in this independent auditors’ review report are Han, Yi-Lien and Chang, Stu-Ying.

KPMG

Taipei, Taiwan (Republic of China)
August 5, 2025

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors’ review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors’ review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Balance Sheets

June 30, 2025, December 31, 2024, and June 30, 2024

(Expressed in Thousands of New Taiwan Dollar)

		June 30, 2025		December 31, 2024		June 30, 2024				June 30, 2025		December 31, 2024		June 30, 2024	
Assets		Amount	%	Amount	%	Amount	%	Liabilities and Equity		Amount	%	Amount	%	Amount	%
Current assets:								Current liabilities:							
1100	Cash and cash equivalents (notes 6(a), (f) and (t))	\$ 2,555,791	24	2,772,615	25	2,573,789	25	2100	Short-term borrowings (notes 6(k) and (t))	\$ 1,700,000	16	1,200,000	11	2,000,000	20
1120	Current financial assets at fair value through other comprehensive income (notes 6(b) and (t))	45,131	-	77,015	1	272,600	3	2130	Contract liabilities-current (note 6(q))	32,585	-	34,340	-	12,561	-
1150	Notes receivable, net (notes 6(c), (f) and (t))	23,313	-	22,847	-	32,502	-	2150	Notes payable (notes 6(f) and (t))	17,619	-	50,399	-	72,647	1
1170	Accounts receivable, net (notes 6(c), (f) and (t))	1,207,692	12	1,323,440	12	1,228,406	12	2170	Accounts payable (notes 6(f) and (t))	227,476	2	275,759	3	135,147	1
1180	Accounts receivable due from related parties, net (notes 6(c), (t) and 7)	46,043	-	7,385	-	22,677	-	2216	Dividends payable (note 6(t))	40,287	-	-	-	21,390	-
1200	Other receivables, net (notes 6(t) and 7)	176,130	2	23,181	-	66,878	1	2219	Other payables (notes 6(r) and (t))	582,874	6	649,139	6	533,858	5
130X	Inventories (notes 6(d), (f) and 9)	1,264,363	12	1,270,007	12	1,116,122	11	2230	Current tax liabilities (note 6(f))	229,651	2	228,802	2	172,361	2
1410	Prepayments	79,266	1	57,911	1	74,113	1	2280	Current lease liabilities (notes 6(f) and (t))	6,976	-	930	-	6,699	-
1476	Other current financial assets (notes 6(f), (j) and (t))	332,000	3	232,000	2	127,000	1	2300	Other current liabilities (note 6(f))	20,224	-	23,040	-	29,554	-
1470	Other current assets (note 6(j))	25,822	-	6,667	-	19,503	-	2320	Long-term liabilities, current portion (notes 6(l) and (t))	400,000	4	400,000	4	-	-
		<u>5,755,551</u>	<u>54</u>	<u>5,793,068</u>	<u>53</u>	<u>5,533,590</u>	<u>54</u>			<u>3,257,692</u>	<u>30</u>	<u>2,862,409</u>	<u>26</u>	<u>2,984,217</u>	<u>29</u>
Non-current assets:								Non-current liabilities:							
1517	Non-current financial assets at fair value through other comprehensive income (notes 6(b) and (t))	204,003	2	198,205	2	194,436	2	2540	Long-term borrowings (notes 6(l) and (t))	100,000	1	100,000	1	400,000	4
1550	Investments accounted for using the equity method, net (note 6(e))	1,567,783	15	1,719,819	16	1,372,323	14	2570	Deferred tax liabilities	359,240	4	359,239	3	318,745	3
1600	Property, plant and equipment (notes 6(f), (h) and 9)	2,179,238	20	2,235,004	21	2,268,189	22	2580	Non-current lease liabilities (notes 6(f) and (t))	7,684	-	10,199	-	2,121	-
1755	Right-of-use assets (note 6(f))	14,615	-	11,116	-	8,822	-	2640	Net defined benefit liability, non-current	17,323	-	17,539	-	27,031	-
1760	Investment property, net	129,717	1	132,194	1	132,727	1	2645	Guarantee deposits received (note 6(t))	2,424	-	2,440	-	2,438	-
1780	Intangible assets (notes 6(f), (i) and 9)	423,909	4	371,341	3	397,963	4	2670	Other non-current liabilities (note 6(t))	-	-	-	-	5,800	-
1840	Deferred tax assets	58,505	1	58,523	1	48,708	-			<u>486,671</u>	<u>5</u>	<u>489,417</u>	<u>4</u>	<u>756,135</u>	<u>7</u>
1915	Prepayments for business facilities	50,019	-	40,233	-	5,600	-		Total liabilities	<u>3,744,363</u>	<u>35</u>	<u>3,351,826</u>	<u>30</u>	<u>3,740,352</u>	<u>36</u>
1920	Refundable deposits paid (note 6(t))	30,451	-	30,463	-	34,250	-	Equity attributable to owners of parent (note 6(o)):							
1984	Other non-current financial assets (notes 6(j), (t) and 8)	176,695	2	176,817	2	177,064	2	3100	Share capital	2,486,500	23	2,486,500	23	2,486,500	24
1990	Other non-current assets (notes 6(f), (j) and 9)	79,779	1	95,983	1	76,208	1	3200	Capital surplus (note 6(e))	317,494	3	317,036	3	316,969	3
		<u>4,914,714</u>	<u>46</u>	<u>5,069,698</u>	<u>47</u>	<u>4,716,290</u>	<u>46</u>	3310	Legal reserve	1,657,165	15	1,499,516	14	1,499,516	15
								3320	Special reserve	198,071	2	198,071	2	198,071	2
								3350	Unappropriated retained earnings	1,664,367	16	2,190,637	20	1,156,627	11
								3400	Other equity interest	(140,847)	(1)	58,688	1	148,528	2
									Equity attributable to owners of parent:	6,182,750	58	6,750,448	63	5,806,211	57
								36XX	Non-controlling interests (notes 6(g) and (o))	743,152	7	760,492	7	703,317	7
									Total equity	6,925,902	65	7,510,940	70	6,509,528	64
Total assets		<u>\$ 10,670,265</u>	<u>100</u>	<u>10,862,766</u>	<u>100</u>	<u>10,249,880</u>	<u>100</u>	Total liabilities and equity		<u>\$ 10,670,265</u>	<u>100</u>	<u>10,862,766</u>	<u>100</u>	<u>10,249,880</u>	<u>100</u>

See accompanying notes to financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income

For the three months and six months ended June 30, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollar, Except for Earnings Per Share)

		For the three months ended June 30				For the six months ended June 30			
		2025		2024		2025		2024	
		Amount	%	Amount	%	Amount	%	Amount	%
4000	Operating revenue (notes 6(q) and 7)	\$ 1,512,050	100	1,374,651	100	2,970,900	100	2,648,256	100
5000	Operating costs (notes 6(d), (m) and 12)	624,674	41	566,871	41	1,199,070	40	1,067,617	40
	Gross profit	887,376	59	807,780	59	1,771,830	60	1,580,639	60
5910	Less: Unrealized profit (loss) from sales	761	-	(2,632)	-	13,737	-	12,797	1
5920	Add: Realized profit (loss) from sales	-	-	-	-	12,053	-	13,490	1
	Gross profit, net	886,615	59	810,412	59	1,770,146	60	1,581,332	60
6000	Operating expenses (notes (m), (r) and 12):								
6100	Selling expenses	318,305	21	305,563	22	637,242	21	576,673	22
6200	Administrative expenses	117,794	8	136,977	10	221,323	8	241,435	9
6300	Research and development expenses	44,526	3	84,163	6	93,445	3	169,043	6
6450	Expected (reversal of) credit losses (note 6(c))	(425)	-	818	-	(424)	-	1,389	-
	Total operating expenses	480,200	32	527,521	38	951,586	32	988,540	37
	Net operating income	406,415	27	282,891	21	818,560	28	592,792	23
	Non-operating income and expenses (note 6(s)):								
7100	Interest income	19,932	1	23,593	2	37,923	1	43,135	2
7010	Other income	2,756	-	3,056	-	43,417	1	5,696	-
7020	Other gains and losses, net (note 7)	(61,112)	(3)	646	-	(47,254)	(1)	12,968	1
7050	Finance costs, net	(10,195)	(1)	(10,120)	(1)	(18,538)	(1)	(17,484)	(1)
7060	Share of profit of associates accounted for using the equity method, net (note 6(e))	35,835	2	49,450	4	75,119	3	80,463	3
7055	Total non-operating income and expenses	(12,784)	(1)	66,625	5	90,667	3	124,778	5
	Profit before tax	393,631	26	349,516	26	909,227	31	717,570	28
7950	Less: Income tax expenses (note 6(n))	91,994	6	77,539	6	199,508	7	150,867	6
	Profit for the period	301,637	20	271,977	20	709,719	24	566,703	22
8300	Other comprehensive income :								
8310	Components of other comprehensive income (loss) that will not be reclassified to profit or loss								
8316	Unrealized (losses) gains from investments in equity instruments measured at fair value through other comprehensive income	(7,928)	(1)	65,330	4	(26,086)	(1)	193,341	7
8320	Share of other comprehensive income (losses) of associates accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss	9,325	1	(3,984)	-	8,400	-	(2,251)	-
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Components of other comprehensive (losses) income that will not be reclassified to profit or loss	1,397	-	61,346	4	(17,686)	(1)	191,090	7
8360	Components of other comprehensive income (losses) that will be reclassified to profit or loss								
8361	Exchange differences on translation	(225,201)	(15)	25,180	2	(193,442)	(6)	85,431	3
8399	Income tax related to components of other comprehensive (loss) income that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Components of other comprehensive (loss) income that will be reclassified to profit or loss	(225,201)	(15)	25,180	2	(193,442)	(6)	85,431	3
8300	Other comprehensive (loss) income	(223,804)	(15)	86,526	6	(211,128)	(7)	276,521	10
	Total comprehensive income for the period	\$ 77,833	5	358,503	26	498,591	17	843,224	32
	Profit attributable to:								
8610	Owners of parent	\$ 284,656	19	261,711	19	675,752	23	542,482	21
8620	Non-controlling interests	16,981	1	10,266	1	33,967	1	24,221	1
		\$ 301,637	20	271,977	20	709,719	24	566,703	22
	Comprehensive income attributable to:								
	Owners of parent	\$ 64,249	4	319,776	23	475,935	16	734,795	28
	Non-controlling interests	13,584	1	38,727	3	22,656	1	108,429	4
		\$ 77,833	5	358,503	26	498,591	17	843,224	32
	Earnings per share, net of tax (note 6(p))								
9750	Basic earnings per share	\$ 1.14		1.05		2.72		2.18	
9850	Diluted earnings per share	\$ 1.14		1.05		2.71		2.18	

See accompanying notes to financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES**Consolidated Statements of Changes in Equity****For the six months ended June 30, 2025 and 2024****(Expressed in Thousands of New Taiwan Dollar)**

	Equity attributable to owners of parent										
	Share capital		Retained earnings			Total other equity interest					
	Ordinary shares	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings	Exchange differences on translation	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Total other equity interest	Total equity attributable to owners of parent	Non-controlling interests	Total equity
Balance at January 1, 2024	\$ 2,486,500	316,618	1,389,227	198,071	1,594,709	(75,492)	31,707	(43,785)	5,941,340	564,802	6,506,142
Net income	-	-	-	-	542,482	-	-	-	542,482	24,221	566,703
Other comprehensive income	-	-	-	-	-	85,365	106,948	192,313	192,313	84,208	276,521
Total comprehensive income	-	-	-	-	542,482	85,365	106,948	192,313	734,795	108,429	843,224
Appropriation and distribution of retained earnings:											
Legal reserve appropriated	-	-	110,289	-	(110,289)	-	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(870,275)	-	-	-	(870,275)	-	(870,275)
Other changes in capital surplus:											
Changes in equity of investments accounted for using the equity method	-	186	-	-	-	-	-	-	186	-	186
Other changes in capital surplus	-	134	-	-	-	-	-	-	134	-	134
Changes in ownership interests in subsidiaries	-	31	-	-	-	-	-	-	31	23	54
Changes in non-controlling interests	-	-	-	-	-	-	-	-	-	51,453	51,453
Distribution of dividend by subsidiaries to non-controlling interests	-	-	-	-	-	-	-	-	-	(21,390)	(21,390)
Balance at June 30, 2024	\$ 2,486,500	316,969	1,499,516	198,071	1,156,627	9,873	138,655	148,528	5,806,211	703,317	6,509,528
Balance at January 1, 2025	\$ 2,486,500	317,036	1,499,516	198,071	2,190,637	31,316	27,372	58,688	6,750,448	760,492	7,510,940
Net income	-	-	-	-	675,752	-	-	-	675,752	33,967	709,719
Other comprehensive income	-	-	-	-	-	(193,483)	(6,334)	(199,817)	(199,817)	(11,311)	(211,128)
Total comprehensive income	-	-	-	-	675,752	(193,483)	(6,334)	(199,817)	475,935	22,656	498,591
Appropriation and distribution of retained earnings:											
Legal reserve appropriated	-	-	157,649	-	(157,649)	-	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(1,044,330)	-	-	-	(1,044,330)	-	(1,044,330)
Other changes in capital surplus:											
Changes in equity of investments accounted for using the equity method	-	57	-	-	-	-	-	-	57	-	57
Other changes in capital surplus	-	245	-	-	-	-	-	-	245	-	245
Disposal of subsidiaries or investments accounted for using equity method	-	-	-	-	-	282	-	282	282	180	462
Changes in ownership interests in subsidiaries	-	156	-	-	(43)	-	-	-	113	111	224
Distribution of dividend by subsidiaries to non-controlling interests	-	-	-	-	-	-	-	-	-	(40,287)	(40,287)
Balance at June 30, 2025	\$ 2,486,500	317,494	1,657,165	198,071	1,664,367	(161,885)	21,038	(140,847)	6,182,750	743,152	6,925,902

See accompanying notes to financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Statements of Cash Flows

For the six months ended June 30, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollar)

	For the six months ended June 30	
	2025	2024
Cash flows from (used in) operating activities:		
Profit before tax	\$ 909,227	717,570
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expenses	78,697	76,221
Amortization expenses	19,001	17,067
Expected (reversal of) credit impairment losses	(424)	1,389
Interest expenses	18,538	17,484
Interest income	(37,923)	(43,135)
Shares of profit of investments accounted for using the equity method	(75,119)	(80,463)
Gain on disposal of property, plant and equipment	(80)	(138)
Gain on disposal of investments accounted for using equity method	(946)	-
Reversal of impairment loss on non-financial assets	-	(2,000)
Unrealized profit from sales	13,737	12,797
Realized profit from sales	(12,053)	(13,490)
Other	-	(41)
Total adjustments to reconcile profit (loss)	3,428	(14,309)
Changes in operating assets and liabilities:		
Changes in operating assets:		
Notes receivable	(466)	5,546
Accounts receivable	76,562	114,340
Other receivables	2,472	(1,691)
Inventories	5,503	(7,403)
Prepayments and other current assets	(42,379)	(4,611)
Total changes in operating assets	41,692	106,181
Changes in operating liabilities:		
Contract liabilities	(1,746)	(1,673)
Notes payable	(32,780)	(12,601)
Accounts payable	(47,855)	(150,492)
Other payable	(65,770)	(120,659)
Other current liabilities	(2,408)	12,843
Net defined benefit liability	(216)	(371)
Total changes in operating liabilities	(150,775)	(272,953)
Total changes in operating assets and liabilities	(109,083)	(166,772)
Total adjustments	(105,655)	(181,081)
Cash inflow generated from operations	803,572	536,489
Interest received	37,270	45,853
Dividends received	36,752	23,369
Interest paid	(18,133)	(17,247)
Income taxes paid	(198,719)	(142,015)
Net cash flows from operating activities	660,742	446,449
Cash flows from (used in) investing activities:		
Net cash outflow from acquisition of subsidiaries	-	(242,870)
Proceeds from disposal of subsidiaries	1,470	-
Acquisition of property, plant and equipment	(19,007)	(41,397)
Proceeds from disposal of property, plant and equipment	1,133	2,276
Decrease in refundable deposits paid	4	16,501
Acquisition of intangible assets	(35,651)	(2,350)
(Increase) decrease in other financial assets	(99,878)	14,301
Increase in prepayments for business facilities	(9,882)	(1,843)
(Increase) decrease in other non-current assets	(17,951)	2,003
Net cash flows used in investing activities	(179,762)	(253,379)
Cash flows from (used in) financing activities:		
Increase in short-term loans	3,750,000	4,650,000
Decrease in short-term loans	(3,250,000)	(4,100,000)
(Decrease) increase in guarantee deposits received	(6)	6
Payment of lease liabilities	(4,096)	(4,855)
Cash dividends paid	(1,044,330)	(870,275)
Dividends unclaimed by shareholders	-	188
Net cash flows used in financing activities	(548,432)	(324,936)
Effect of exchange rate changes on cash and cash equivalents	(149,372)	84,635
Net decrease in cash and cash equivalents	(216,824)	(47,231)
Cash and cash equivalents at beginning of period	2,772,615	2,621,020
Cash and cash equivalents at end of period	\$ 2,555,791	2,573,789

See accompanying notes to financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

June 30, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollar, Unless Otherwise Specified)

(1) Company history

TTY Biopharm Company Limited (the “Company”) was established on July 22, 1960. The Company’s registered office address is 3F., No. 3-1, Park St., Nangang Dist., Taipei City 115, Taiwan. The main activities of the Company and its subsidiaries (the “Group”) are producing a variety of pharmaceuticals and chemical drugs. Please refer to Note 14.

(2) Approval date and procedures of the consolidated financial statements:

The consolidated financial statements were authorized for issuance by the Board of Directors on August 5, 2025.

(3) New standards, amendments and interpretations adopted:

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2025:

- Amendments to IAS21 “Lack of Exchangeability”

- (b) The impact of IFRS Accounting Standards endorsed by the FSC but not yet effective

The Group assesses that the adoption of the following new amendments, effective for annual period beginning on January 1, 2026, would not have a significant impact on its consolidated financial statements:

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (c) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none"> • A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities. • Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards. • Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes. 	January 1, 2027

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures”

(4) Summary of material accounting policies:

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by FSC, and do not include all of the information required by the IFRSs, IASs, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRS endorsed by the FSC) for the annual consolidated financial statements.

Except for the following accounting policies, the significant policies adopted in the consolidated financial statements are consistent with Note 4 in the consolidated financial statement for the year ended December 31, 2024.

(b) Basis of consolidation

(i) List of subsidiaries included in the consolidated financial statements:

Investor	Subsidiary	Nature of business	Shareholding			Notes
			June 30, 2025	December 31, 2024	June 30, 2024	
The Company	Xudong Haipu International Co., Ltd.	Investing activities	100.00 %	100.00 %	100.00 %	
The Company	Worldco International Co., Ltd.	Investing activities and selling medicine	100.00 %	100.00 %	100.00 %	
The Company	American Taiwan Biopharma Philippines Inc.(ATBP)	Selling medicine	87.00 %	87.00 %	87.00 %	
The Company	TSH Biopharm Co., Ltd.(TSH)	Selling medicine	56.48 %	56.48 %	56.48 %	
The Company	EnhanX Biopharm Inc.(EnhanX)	Developing medicine	20.83 %	20.83 %	20.83 %	
The Company	Chuang Yi Biotech Co., Ltd.(CYB)	Selling functional food	23.12 %	23.12 %	23.12 %	
Worldco International Co., Ltd.	Worldco Biotech (Chengdu) Pharmaceutical Ltd.	Selling medicine	100.00 %	100.00 %	100.00 %	

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

Investor	Subsidiary	Nature of business	Shareholding			Notes
			June 30, 2025	December 31, 2024	June 30, 2024	
Worldco International Co., Ltd.	TTY Biopharm Mexico S.A. de C.V.(TTY-Mexico)	Selling medicine	50.00 %	50.00 %	50.00 %	(Note 4)
Xudong Haipu International Co., Ltd.	EnhanX Biopharm Inc.(EnhanX)	Developing medicine	29.17 %	29.17 %	29.17 %	
Xudong Haipu International Co., Ltd.	TTY Biopharm Korea Co., Ltd. (TTY-Korea)	Selling medicine	100.00 %	100.00 %	100.00 %	
Xudong Haipu International Co., Ltd.	TTY Biopharm Mexico S.A. de C.V.(TTY-Mexico)	Selling medicine	50.00 %	50.00 %	50.00 %	(Note 4)
EnhanX Biopharm Inc.	EnhanX Biopharm B.V.	Developing medicine	- %	100.00 %	100.00 %	(Note 1)
TSH Biopharm Co., Ltd.	Chuang Yi Biotech Co., Ltd.(CYB)	Selling functional food	51.60 %	51.60 %	51.60 %	
TSH Biopharm Co., Ltd.	TOP Pharm Medicalware Co., Ltd.(TOP PM)	Selling and manufacturing of medicine and functional food	51.00 %	51.00 %	51.00 %	(Note 2 and 3)
TSH Biopharm Co., Ltd.	TOP Biological Technology Co., Ltd.(TOP BT)	Food manufacturing	- %	51.00 %	51.00 %	(Note 2 and 3)
Chuang Yi Biotech Co., Ltd.	Immortal Fame Global Ltd.	Import and export trading and investment activities	- %	100.00 %	100.00 %	(Note 5)
Immortal Fame Global Ltd.	Chuang Yi (Shanghai) Trading Co., Ltd.	Selling functional food	- %	100.00 %	100.00 %	(Note 5)

(Note 1) In order to reduce the operating costs of the Group, a resolution was decided by the Board of Directors of EnhanX on December 28, 2023 to liquidate EnhanX B.V. and the liquidation has been completed and filed with the Ministry of Economic Affairs on April 21, 2025.

(Note 2) TSH acquired 51% ordinary shares outstanding of each TOP Pharm Medicalware Co., Ltd. (TOP PM) and TOP Biological Technology Co., Ltd. (TOP BT) on April 9, 2024, resulting in both subsidiaries to be included in the Group's consolidated financial report.

(Note 3) To enhance the integration of the Group's resources, the Board of Directors of TSH resolved on November 8, 2024, to approve the merger of TOP PM and TOP BT, with TOP PM as the surviving entity and TOP BT as the dissolving entity. The effective date of the merger was set for January 1, 2025, and the change was approved by the competent authorities on March 3, 2025.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(Note4) In order to reduce the operating costs of the Group, the Board of Directors has resolved to liquidate TTY-Mexico. The liquidation procedures are still in progress.

(Note5) The Group's Board of Directors has resolved to dispose of the entity, and the disposal was completed on January 6, 2025.

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

(c) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events.

(d) Income taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of IAS 34 “Interim Financial Reporting”.

Income tax expenses for the period are best estimated by multiplying pre-tax income for the interim reporting period using the effective annual tax rate as forecasted by the management. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IAS 34 “Interim Financial Reporting” endorsed by the FSC requires management to make judgments, and estimates about the future, including climate-related risks and opportunities, that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Except for the following, the preparation of the consolidated interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2024. For related information, please refer to Note 5 of the consolidated financial statements for the year ended December 31, 2024.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(6) Explanation of significant accounts:

Except for the following disclosures, there were no material differences in the disclosures of significant accounts between the consolidated interim financial statements for the current period and the consolidated financial statements for the year ended December 31, 2024. Please refer to Note 6 of the consolidated financial statements for the year ended December 31, 2024.

(a) Cash and cash equivalents

	June 30, 2025	December 31, 2024	June 30, 2024
Cash on hand	\$ 2,506	2,621	2,277
Cash in banks	1,264,085	1,327,454	1,403,312
Time deposits	1,289,200	1,442,540	1,168,200
Total	<u><u>\$ 2,555,791</u></u>	<u><u>2,772,615</u></u>	<u><u>2,573,789</u></u>

- (i) The above cash and cash equivalents were not pledged as collateral.
- (ii) Time deposits which do not meet the definition of cash equivalents are accounted for under other financial assets-current, please refer to Note 6(j).
- (iii) Please refer to Note 6(t) for the fair value sensitivity analysis and interest rate risk of the financial assets and liabilities of the Group.

(b) Financial asset at fair value through other comprehensive income-current and non-current

	June 30, 2025	December 31, 2024	June 30, 2024
The equity investments at fair value through other comprehensive income:			
Domestic common stock—Lumosa Therapeutics Co., Ltd.	\$ 45,131	77,015	272,600
Domestic preferred stock—Fubon Financial Holding Co., Ltd. Preferred Shares B	156,500	151,250	149,000
Domestic preferred stock—Fubon Financial Holding Co., Ltd. Preferred Shares C	3,072	3,084	3,107
Domestic preferred stock—Union Bank of Taiwan Preferred Shares A	21,960	21,400	21,320
International unlisted stock—CellMax Ltd.	10,479	10,479	9,017
Domestic unlisted stock—ExoOne Bio. Co., Ltd.	11,992	11,992	11,992
	<u><u>\$ 249,134</u></u>	<u><u>275,220</u></u>	<u><u>467,036</u></u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (i) The Group designated the investments as equity securities at fair value through other comprehensive income because the Group intends to hold the investments for long-term strategic and not for trading purposes.
 - (ii) For the years ended December 31, 2025 and 2024, the Group did not participate in the capital increase of ExoOne Bio. Co., Ltd., resulting in a decrease in its shareholding ratio to 2.46%.
 - (iii) There were no disposals of strategic investments and transfers of any cumulative gain or loss within equity relating to these investments for the six months ended June 30, 2025 and 2024.
 - (iv) Please refer to Note 6(t) for information on credit and market risk.
 - (v) The above financial assets were not pledged as collateral.
- (c) Notes receivable and accounts receivable (including related parties)

	June 30, 2025	December 31, 2024	June 30, 2024
Notes receivable	\$ 23,348	22,872	32,603
Accounts receivable	1,210,932	1,327,128	1,232,041
Accounts receivable-related parties	46,043	7,385	22,677
Less: allowance for expected credit losses	(3,275)	(3,713)	(3,736)
	<u><u>\$ 1,277,048</u></u>	<u><u>1,353,672</u></u>	<u><u>1,283,585</u></u>

The Group applies the simplified approach to evaluating its expected credit losses (ECLs), i.e., the Group recognizes the impairment provision for lifetime ECLs for all receivables. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics that represent the customer's ability to pay all amounts due under the terms of the contract, and forward-looking information has been incorporated. Analysis of the expected credit losses on note and accounts receivable is as follows:

	June 30, 2025		
	Face value of notes receivable and accounts receivable	Weighted average loss rate	Allowance for expected credit losses
Not overdue	\$ 1,276,557	0%~1%	2,107
1 to 90 days overdue	3,517	1%~21.29%	919
More than 181 days overdue	249	100%	249
	<u><u>\$ 1,280,323</u></u>		<u><u>3,275</u></u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	December 31, 2024		
	Face value of notes receivable and accounts receivable	Weighted average loss rate	Allowance for expected credit losses
Not overdue	\$ 1,356,374	0%~1.29%	3,449
1 to 90 days overdue	671	0%~1%	2
91 to 180 days overdue	78	0%~56.5%	-
More than 181 days overdue	262	100%	262
	<u>\$ 1,357,385</u>		<u>3,713</u>

	June 30, 2024		
	Face value of notes receivable and accounts receivable	Weighted average loss rate	Allowance for expected credit losses
Not overdue	\$ 1,282,066	0%~1.82%	2,556
1 to 90 days overdue	3,255	1%~1.65%	51
91 to 180 days overdue	1,742	1%~50%	871
More than 181 days overdue	258	100%	258
	<u>\$ 1,287,321</u>		<u>3,736</u>

The movements in the allowance for notes and accounts receivable were as follows:

	For the six months ended June 30,	
	2025	2024
Balance at January 1	\$ 3,713	2,347
Expected credit losses recognized	-	1,389
Reversal of expected credit losses	(424)	-
Effect of changes in foreign exchange rates	(14)	-
Balance at June 30	<u>\$ 3,275</u>	<u>3,736</u>

As of June 30, 2025, December 31, 2024 and June 30, 2024, the notes receivable and accounts receivable for the Group were not pledged as collateral.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(d) Inventories

	June 30, 2025	December 31, 2024	June 30, 2024
Merchandise	\$ 251,984	379,722	312,575
Finished goods	272,164	306,371	228,289
Work in process	283,287	231,394	250,654
Raw materials	355,632	298,873	238,930
Materials	<u>65,732</u>	<u>67,111</u>	<u>72,175</u>
Subtotal	1,228,799	1,283,471	1,102,623
Goods in transit	<u>122,748</u>	<u>115,276</u>	<u>117,941</u>
Total	1,351,547	1,398,747	1,220,564
Less: allowance for inventory market decline and obsolescence	<u>(87,184)</u>	<u>(128,740)</u>	<u>(104,442)</u>
Net amount	<u><u>\$ 1,264,363</u></u>	<u><u>1,270,007</u></u>	<u><u>1,116,122</u></u>

(i) The details of operating costs were as follows:

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Inventories have been sold \$	619,026	558,408	1,206,219	1,050,847
Cost of services	274	376	564	753
Reversal gains on inventory write-down and disposal losses	5,374	8,087	(7,713)	16,017
	<u>\$ 624,674</u>	<u>566,871</u>	<u>1,199,070</u>	<u>1,067,617</u>

As of June 30, 2025, December 31, 2024 and June 30, 2024, the inventories were not pledged as collateral.

(e) Investments accounted for using the equity method

(i) The components of investments accounted for using the equity method at the reporting date were as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Associates	<u><u>\$ 1,567,783</u></u>	<u><u>1,719,819</u></u>	<u><u>1,372,323</u></u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- 1) As of June 30, 2025, December 31, 2024 and June 30, 2024, the associate which the Group invested had a quoted market price was as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Carrying value	\$ <u>1,002,775</u>	<u>1,136,242</u>	<u>864,296</u>
Fair value	\$ <u>2,017,611</u>	<u>2,335,773</u>	<u>2,522,014</u>

- 2) For the six months ended June 30, 2025 and 2024, as PharmaEngine, Inc. amortized the compensation cost of employee stock options and the employee stock options expired, the Group's equity has changed and its capital reserve was credit by \$57 thousand and \$186 thousand, respectively.

For the six months ended June 30, 2025 and 2024, the Group's shareholding ratio had no change.

- (ii) Associate that had materiality was as follows:

Associate	Nature of relationship	Country of registration	Equity ownership		
			June 30, 2025	December 31, 2024	June 30, 2024
PharmaEngine, Inc.	Research for new drugs and drug development especially for Asian diseases	Taiwan	18.00 %	18.00 %	18.00 %

The following was the summary of financial information about the Group's significant associates, adjusted for the amounts included in the Group's IFRS financial statements to reflect the fair value adjustments made upon acquisition of the shares in the associates and adjustments for differences in accounting policies:

- Summary financial information on PharmaEngine, Inc.

	June 30, 2025	December 31, 2024	June 30, 2024
Current assets	\$ 5,691,018	5,827,444	4,190,923
Non-current assets	25,356	20,367	25,749
Current liabilities	(1,057,313)	(443,053)	(320,632)
Non-current liabilities	(744)	(4,960)	(7,051)
Net assets	\$ <u>4,658,317</u>	<u>5,399,798</u>	<u>3,888,989</u>
Net assets attributable to investee's owners	\$ <u>4,658,317</u>	<u>5,399,798</u>	<u>3,888,989</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Operating revenue	\$ <u>196,787</u>	<u>261,902</u>	<u>384,169</u>	<u>426,373</u>
Profit from continuing operations	\$ 17,785	158,868	120,088	240,594
Other comprehensive loss	-	-	-	-
Total comprehensive income	\$ <u>17,785</u>	<u>158,868</u>	<u>120,088</u>	<u>240,594</u>
Comprehensive income attributable to investee's owners	\$ <u>17,785</u>	<u>158,868</u>	<u>120,088</u>	<u>240,594</u>

	For the six months ended June 30,	
	2025	2024
Net assets attributable to the Group, January 1	\$ 971,964	695,325
Changes in capital surplus of associates	57	186
Comprehensive income attributable to the Group	21,622	43,307
Cash dividends received from associates	(155,146)	(38,800)
Net assets attributable to the Group, June 30	838,497	700,018
Add: Goodwill	164,278	164,278
Carrying amount of interest in associates, June 30	\$ <u>1,002,775</u>	<u>864,296</u>

(iii) Summary financial information on individually insignificant associates

The Group's financial information about investments accounted for using the equity method that are individually insignificant was as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Carrying amount of individually insignificant associates	\$ <u>565,008</u>	<u>583,577</u>	<u>508,027</u>

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Attributable to the Group:				
Profit from continuing operations	\$ 32,634	20,853	53,503	37,156
Other comprehensive income (loss)	(44,923)	(1,199)	(33,638)	(2,588)
Total comprehensive income	\$ <u>(12,289)</u>	<u>19,654</u>	<u>19,865</u>	<u>34,568</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iv) Collateral

As of June 30, 2025, December 31, 2024 and June 30, 2024, the Group did not provide any investment accounted for using equity method as collateral.

(f) Business combination

On April 9, 2024 (the acquisition date), the Group acquired 51% ordinary shares outstanding of each TOP PM and TOP BT, both companies engaged in the manufacturing and sales of health supplements, for a consideration price of \$301,451 thousand, resulting in the Group to obtain control over them.

The acquisition of both subsidiaries will expand the Group's scale of business operations, improve its operating performance and increase its competitiveness.

(i) Consideration transferred

	TOP PM	TOP BT
Cash	<u><u>\$ 257,121</u></u>	<u><u>44,330</u></u>

(ii) The following table summarizes the recognized amounts of identifiable assets acquired and liabilities assumed at the acquisition date.

	TOP PM	TOP BT
Cash and cash equivalents	\$ 55,135	3,446
Notes and accounts receivable	49,520	11,255
Inventories	5,185	7,584
Other financial assets	25,000	-
Property, plant and equipment	215	4,967
Right-of-use assets	4,955	1,949
Intangible assets	318	-
Other non-current assets	2,894	3,640
Notes and accounts payable	(37,105)	(11,391)
Lease liabilities	(5,049)	(2,023)
Current tax liabilities	(5,356)	(1,182)
Other current liabilities	<u>(8,397)</u>	<u>(554)</u>
	<u><u>\$ 87,315</u></u>	<u><u>17,691</u></u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iii) Goodwill

Goodwill arising from the acquisition has been recognized as follows.

	<u>TOP PM</u>	<u>TOP BT</u>
Consideration transferred	\$ 257,121	44,330
Add: Non-controlling interest in the acquiree, if any (proportionate share of the fair value of the identifiable net assets)	42,784	8,669
Less: Fair value of identifiable net assets	<u>(87,315)</u>	<u>(17,691)</u>
Goodwill	<u><u>\$ 212,590</u></u>	<u><u>35,308</u></u>

(g) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

Subsidiary	Country of registration	Non-controlling interests and voting rights ratio		
		June 30, 2025	December 31, 2024	June 30, 2024
TSH Biopharm Co., Ltd.	Taiwan	43.52 %	43.52 %	43.52 %

The following information of the aforementioned subsidiaries have been prepared in accordance with the IFRS endorsed by the FSC, which was included in the fair value adjustments and the adjustments of differences in accounting principles at the acquisition date. Intra-group transactions were not eliminated in this information.

(i) Summary financial information on TSH Biopharm Co., Ltd.

	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
Current assets	\$ 1,305,199	1,304,702	1,198,903
Non-current assets	546,749	537,491	538,044
Current liabilities	(264,143)	(208,895)	(222,266)
Non-current liabilities	<u>(9,401)</u>	<u>(10,330)</u>	<u>(1,938)</u>
Net assets	<u><u>\$ 1,578,404</u></u>	<u><u>1,622,968</u></u>	<u><u>1,512,743</u></u>
Net assets attributable to non- controlling interest	<u><u>\$ 743,561</u></u>	<u><u>760,554</u></u>	<u><u>694,266</u></u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Operating revenue	\$ <u>269,296</u>	<u>235,589</u>	<u>556,414</u>	<u>436,081</u>
Profit for the period	\$ 31,573	15,787	67,349	50,755
Other comprehensive (loss) income	(7,928)	65,347	(26,086)	193,398
Total comprehensive income	\$ <u>23,645</u>	<u>81,134</u>	<u>41,263</u>	<u>244,153</u>
Profit attributable to non- controlling interest	\$ <u>16,977</u>	<u>10,482</u>	<u>34,440</u>	<u>25,138</u>
Total comprehensive income attributable to non-controlling interest	\$ <u>13,527</u>	<u>38,922</u>	<u>23,088</u>	<u>109,307</u>

	For the six months ended June 30,	
	2025	2024
Cash flows from operating activities	\$ 69,435	70,285
Cash flows used in investing activities	(107,519)	(229,695)
Cash flows used in financing activities	(6,082)	(5,641)
Effect of changes in foreign exchange rates	-	43
Net decrease in cash	\$ <u>(44,166)</u>	<u>(165,008)</u>

(h) Property, plant and equipment

The details of the property, plant and equipment of the Group for the six months ended June 30, 2025 and 2024 were as follows:

	Land	Building and construction	Machinery equipment	Transportation equipment	Office equipment	Other equipment	Construction in progress	Total
Cost:								
Balance on January 1, 2025	\$ 902,897	1,479,424	823,121	2,585	595,765	24,065	588	3,828,445
Additions	-	6,392	859	-	6,997	873	3,886	19,007
Disposals	-	(1,100)	(713)	-	(15,524)	(803)	-	(18,140)
Disposal of subsidiary	-	-	(459)	-	-	-	-	(459)
Reclassifications	-	-	-	-	684	-	(588)	96
Adjustment for foreign currency translation	-	-	-	-	(57)	(10)	-	(67)
Balance on June 30, 2025	\$ <u>902,897</u>	<u>1,484,716</u>	<u>822,808</u>	<u>2,585</u>	<u>587,865</u>	<u>24,125</u>	<u>3,886</u>	<u>3,828,882</u>
Balance on January 1, 2024	\$ 902,897	1,461,122	836,063	5,085	570,870	19,806	8,945	3,804,788
Obtained from business combination	-	-	9,591	-	1,096	9,774	-	20,461
Additions	-	3,759	5,597	-	11,518	-	20,523	41,397
Disposals	-	-	(78,477)	(2,500)	(2,895)	(15)	-	(83,887)
Reclassifications	-	-	3,496	-	3,784	-	7,242	14,522
Adjustment for foreign currency translation	-	-	12	-	(2)	-	-	10
Balance on June 30, 2024	\$ <u>902,897</u>	<u>1,464,881</u>	<u>776,282</u>	<u>2,585</u>	<u>584,371</u>	<u>29,565</u>	<u>36,710</u>	<u>3,797,291</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	<u>Land</u>	<u>Building and construction</u>	<u>Machinery equipment</u>	<u>Transportation equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>	<u>Construction in progress</u>	<u>Total</u>
Depreciation and impairment:								
Balance on January 1, 2025	\$ -	645,120	494,322	2,585	433,273	18,141	-	1,593,441
Disposals	-	(1,100)	(662)	-	(14,757)	(568)	-	(17,087)
Depreciation for the year	-	34,553	20,379	-	17,882	978	-	73,792
Disposal of subsidiary	-	-	(436)	-	-	-	-	(436)
Adjustment for foreign currency translation	-	-	-	-	(56)	(10)	-	(66)
Balance on June 30, 2025	<u>\$ -</u>	<u>678,573</u>	<u>513,603</u>	<u>2,585</u>	<u>436,342</u>	<u>18,541</u>	<u>-</u>	<u>1,649,644</u>
Balance on January 1, 2024	\$ -	575,736	529,000	5,085	405,250	11,603	-	1,526,674
Obtained from business combination	-	-	5,580	-	938	8,761	-	15,279
Depreciation for the year	-	33,083	18,603	-	17,607	1,596	-	70,889
Impairment loss	-	-	(2,000)	-	-	-	-	(2,000)
Disposals	-	-	(76,477)	(2,500)	(2,761)	(11)	-	(81,749)
Adjustment for foreign currency translation	-	-	11	-	(2)	-	-	9
Balance on June 30, 2024	<u>\$ -</u>	<u>608,819</u>	<u>474,717</u>	<u>2,585</u>	<u>421,032</u>	<u>21,949</u>	<u>-</u>	<u>1,529,102</u>
Carrying value:								
Balance on January 1, 2025	<u>\$ 902,897</u>	<u>834,304</u>	<u>328,799</u>	<u>-</u>	<u>162,492</u>	<u>5,924</u>	<u>588</u>	<u>2,235,004</u>
Balance on June 30, 2025	<u>\$ 902,897</u>	<u>806,143</u>	<u>309,205</u>	<u>-</u>	<u>151,523</u>	<u>5,584</u>	<u>3,886</u>	<u>2,179,238</u>
Balance on January 1, 2024	<u>\$ 902,897</u>	<u>885,386</u>	<u>307,063</u>	<u>-</u>	<u>165,620</u>	<u>8,203</u>	<u>8,945</u>	<u>2,278,114</u>
Balance on June 30, 2024	<u>\$ 902,897</u>	<u>856,062</u>	<u>301,565</u>	<u>-</u>	<u>163,339</u>	<u>7,616</u>	<u>36,710</u>	<u>2,268,189</u>

As of June 30, 2025, December 31, 2024 and June 30, 2024, the property, plant and equipment were not pledged as collateral.

(i) Intangible assets

The cost, amortization, and impairment of the intangible assets of the Group for the six months ended June 30, 2025 and 2024, were as follows:

	<u>Computer software</u>	<u>Patent and franchise</u>	<u>Other Intangible assets</u>	<u>Goodwill</u>	<u>Total</u>
Cost:					
Balance on January 1, 2025	\$ 36,483	240,875	77,986	247,898	603,242
Additions	6,155	29,496	-	-	35,651
Disposals	(5,188)	-	-	-	(5,188)
Reclassifications	-	35,919	-	-	35,919
Effect of changes in foreign exchange rate	(2)	-	-	-	(2)
Balance on June 30, 2025	<u>\$ 37,448</u>	<u>306,290</u>	<u>77,986</u>	<u>247,898</u>	<u>669,622</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	Computer software	Patent and franchise	Other Intangible assets	Goodwill	Total
Balance on January 1, 2024	\$ 32,417	249,958	73,804	-	356,179
Obtained from business combination (refer to 6(f))	1,253	-	87	247,898	249,238
Additions	2,350	-	-	-	2,350
Disposals	(1,662)	(9,083)	-	-	(10,745)
Reclassifications	455	-	-	-	455
Balance on June 30, 2024	<u><u>\$ 34,813</u></u>	<u><u>240,875</u></u>	<u><u>73,891</u></u>	<u><u>247,898</u></u>	<u><u>597,477</u></u>
Amortization and impairment loss:					
Balance on January 1, 2025	\$ 19,513	165,753	46,635	-	231,901
Amortization for the period	4,068	7,528	7,405	-	19,001
Disposals	(5,188)	-	-	-	(5,188)
Effect of changes in foreign exchange rate	(1)	-	-	-	(1)
Balance on June 30, 2025	<u><u>\$ 18,392</u></u>	<u><u>173,281</u></u>	<u><u>54,040</u></u>	<u><u>-</u></u>	<u><u>245,713</u></u>
Balance on January 1, 2024	\$ 13,712	157,385	21,073	-	192,170
Obtained from business combination	951	-	71	-	1,022
Amortization for the period	4,121	6,459	6,487	-	17,067
Disposals	(1,662)	(9,083)	-	-	(10,745)
Balance on June 30, 2024	<u><u>\$ 17,122</u></u>	<u><u>154,761</u></u>	<u><u>27,631</u></u>	<u><u>-</u></u>	<u><u>199,514</u></u>
Carrying value:					
Balance on January 1, 2025	<u><u>\$ 16,970</u></u>	<u><u>75,122</u></u>	<u><u>31,351</u></u>	<u><u>247,898</u></u>	<u><u>371,341</u></u>
Balance on June 30, 2025	<u><u>\$ 19,056</u></u>	<u><u>133,009</u></u>	<u><u>23,946</u></u>	<u><u>247,898</u></u>	<u><u>423,909</u></u>
Balance on January 1, 2024	<u><u>\$ 18,705</u></u>	<u><u>92,573</u></u>	<u><u>52,731</u></u>	<u><u>-</u></u>	<u><u>164,009</u></u>
Balance on June 30, 2024	<u><u>\$ 17,691</u></u>	<u><u>86,114</u></u>	<u><u>46,260</u></u>	<u><u>247,898</u></u>	<u><u>397,963</u></u>

As of June 30, 2025, December 31, 2024 and June 30, 2024, the Group's aforementioned intangible assets were not pledged as collateral.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(j) Other financial assets and other assets

	June 30, 2025	December 31, 2024	June 30, 2024
Other current financial assets	\$ 332,000	232,000	127,000
Other non-current financial assets	176,695	176,817	177,064
Long-term prepayments	79,129	94,836	74,520
Other current and non-current assets	<u>26,472</u>	<u>7,814</u>	<u>21,191</u>
	<u>\$ 614,296</u>	<u>511,467</u>	<u>399,775</u>

- (i) Other current financial assets were bank deposits that did not qualify as cash and cash equivalents.
- (ii) Long-term prepayments were paid for intangible assets before the intangible assets are ready for use. Please refer to Note 9 for the relevant unrecognized contractual commitments.
- (iii) Please refer to Note 8 for the Group's information of collateral.

(k) Short-term borrowings

The short-term borrowings were summarized as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Unsecured bank loans	\$ <u>1,700,000</u>	<u>1,200,000</u>	<u>2,000,000</u>
Unused credit line	\$ <u>823,125</u>	<u>1,766,198</u>	<u>1,203,818</u>
Range of interest rates	<u>1.82%~1.89%</u>	<u>1.77%~1.99%</u>	<u>1.72%~1.81%</u>

- (i) For the six months ended June 30, 2025 and 2024, the Group had the additional short-term borrowings amounting to \$3,750,000 thousand with an interest rate of 1.82%~1.89% and \$3,250,000 thousand with an interest rate of 1.72%~1.81%, respectively; the repayment amounted to \$5,950,000 thousand and \$4,100,000 thousand, respectively. Please refer to Note 6(s) for disclosure of interest expense.
- (ii) Please refer to Note 6(t) for the exposure information of the Group's interest rate and liquidity risk.

(l) Long-term borrowings

The long-term borrowings were summarized as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Unsecured bank loans	\$ 500,000	500,000	400,000
Less: Current portion	(400,000)	(400,000)	-
Total	<u>\$ 100,000</u>	<u>100,000</u>	<u>400,000</u>
Unused long-term credit line	<u>-</u>	<u>-</u>	<u>100,000</u>
Range of interest rates	<u>2.1%~2.13%</u>	<u>2.066%~2.13%</u>	<u>1.98%</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

There were no significant issues, repurchases and repayments of long-term borrowings six months ended June 30, 2025 and 2024. Please refer to Note 6(s) for related disclosure of interest expense, Note 6(t) for related risk exposure information.

(m) Employee benefits

(i) Defined benefit plans

Management believes that there was no material volatility of the market, material reimbursement and settlement or other material one-time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2024 and 2023.

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Operating cost	\$ 23	39	46	77
Selling expenses	15	20	30	39
Administrative expenses	16	16	32	33
Research and development expenses	8	8	16	17
Total	<u>\$ 62</u>	<u>83</u>	<u>124</u>	<u>166</u>

(ii) Defined contributions plans

The Group's pension expenses under defined contribution plans, which had been allocated to the Bureau of Labor Insurance were as follows:

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Operating cost	\$ 3,594	3,522	6,973	6,721
Selling expenses	4,815	3,840	9,529	7,815
Administrative expenses	2,073	2,847	4,166	4,939
Research and development expenses	1,072	1,135	2,143	2,291
Total	<u>\$ 11,554</u>	<u>11,344</u>	<u>22,811</u>	<u>21,766</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(n) Income tax

(i) Income tax expense

The components of income tax for the six months ended June 30, 2025 and 2024 were as follows:

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Current tax expense				
Current period	\$ 91,955	77,334	199,467	150,820
Adjustment for prior periods	39	205	41	47
Income tax expense from continuing operations	<u>\$ 91,994</u>	<u>77,539</u>	<u>199,508</u>	<u>150,867</u>

(ii) Assessment of tax

Company's income tax returns through 2022 have been assessed and approved by the Tax Authorities. The income tax returns of TSH, CYB, TOP PM, and EnhanX have been assessed and approved by the Tax Authorities through 2023.

(o) Capital and other equity

There was no significant change in capital and other equity for the six months ended June 30, 2025 and 2024. For the related information, please refer to Note 6(p) of the consolidated financial statements for the year ended December 31, 2024.

(i) Capital surplus

The ending balances of additional paid-in capital were as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Share capital	\$ 484	484	484
Long-term investment	315,719	315,506	315,439
Other	1,291	1,046	1,046
	<u>\$ 317,494</u>	<u>317,036</u>	<u>316,969</u>

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(ii) Retained earnings

According to the Articles of Incorporation, the current year's earnings, if any, at the end of fiscal year, shall pay tax first and recover accumulated losses before contributing 10% for legal reserve. However, this shall not be applied if legal reserve hereto has already reached the amount of share capital. After residual amount from aforementioned calculation is added to unappropriated earnings from previous period, a contribution or reversal to special reserved shall then be conducted in accordance with regulations or competent authority's requirements. At the end of each fiscal year, the Board of Directors will propose an earnings distribution based on considerations of the Company's profits, capital and financial structure, future business needs, accumulated earnings and legal reserve, market competition conditions as well as shareholders' interests. The proposal hereto shall be submitted to Annual General Meeting for resolution before being executed accordingly.

The Company adopts the principle of conservative dividend policy. In the event of surplus from the Company's annual account, a contribution of no less than 70% of the balance remaining after the tax payment, the accumulated loss recovery, the contribution of legal reserve and the contribution or reversal of special reserve as required by laws, less the share of profit recognized under the equity method from associates, and plus cash dividends distributed to the Company by those associates recognized under the equity method, shall be distributed as shareholders' dividends in the form of cash or stocks. The percentage for cash dividends shall not less than 70% of the total dividend amount.

Based on the Company's principles of stability for financial structure and dividend balance, the Company may distribute all or part of reserve or retained earnings from previous period in accordance with laws or competent authority's requirements in the event that there is no surplus for distribution in current period, or there is surplus but surplus amount is obviously lower than the Company's surplus actually distributed in the previous year. In the event of disposal of real estate, equity investments or intangible assets in the current year, all or a portion of difference between disposal amount and acquisition cost, or income received from litigation or commercial dispute, can be retained accordingly. Restrictions on distribution percentage shall not apply.

The Company distributes dividends and bonuses or all or part of the statutory surplus reserve and capital reserve in cash by authorizing the Board of Directors to do so with the presence of at least two-thirds of the directors and with the consent of a majority of the directors present, and report to the shareholders' meeting.

1) Legal reserve

When the Company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

2) Special reserve

The Company has selected to apply the optional exemptions according to IFRS 1 “First-time Adoption of International Financial Reporting Standards”.

In accordance with Rule No. 1010012865 issued by the FSC on April 6, 2012, a special reserve was appropriated from the undistributed earnings equivalent to the debit balance of cumulative translation differences of \$82,429 thousand and unrealized revaluation increments of \$27,725 thousand. When relevant assets are used, disposed or reclassified, the original proportion of the special reserve can be reversed to distribute surplus.

In accordance with the aforesaid Rule, a special reserve is set aside from the current year’s net income after tax and prior year’s undistributed earnings at an amount equal to the debit balance of contra accounts in shareholders’ equity. When the debit balance of any of these contra accounts in shareholders’ equity is reversed, the related special reserve can be reversed. The subsequent reversals of contra accounts in shareholder’s equity shall qualify for additional distributions.

As of June 30, 2025, December 31, 2024 and June 30, 2024, all of the special reserve amounted to \$198,071 thousand.

3) Earnings distribution

Earnings distribution for 2024 and 2023 was resolved in the special resolution of the Board of Directors on February 25, 2025 and March 8, 2024, respectively. The appropriation for dividends to ordinary shareholders is as follows:

	2024		2023	
	Amount per share (dollars)	Amount	Amount per share (dollars)	Amount
Dividends distributed to ordinary shareholders:				
Cash	\$ 4.20	<u>1,044,330</u>	3.50	<u>870,275</u>

(iii) Other equity accounts (net value after tax)

	Exchange differences on translation	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Total
Balance at January 1, 2025	\$ 31,316	27,372	58,688
Exchange differences on foreign operations	(193,483)	-	(193,483)
Disposal of subsidiaries	282	-	282
Unrealized losses from financial assets measured at fair value through other comprehensive income	-	(14,734)	(14,734)
Unrealized gains from financial assets measured at fair value through other comprehensive income, associates accounted for using equity method	-	8,400	8,400
Balance at June 30, 2025	<u>\$ (161,885)</u>	<u>21,038</u>	<u>(140,847)</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	Exchange differences on translation	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Total
Balance at January 1, 2024	\$ (75,492)	31,707	(43,785)
Exchange differences on foreign operations	85,365	-	85,365
Unrealized gains from financial assets measured at fair value through other comprehensive income	-	109,199	109,199
Unrealized losses from financial assets measured at fair value through other comprehensive income, associates accounted for using the equity method	-	(2,251)	(2,251)
Balance at June 30, 2024	<u>\$ 9,873</u>	<u>138,655</u>	<u>148,528</u>

(iv) Non-controlling interests

	For the six months ended June 30,	
	2025	2024
Balance at January 1	\$ 760,492	564,802
Attributable to non-controlling interests:		
Profit for the period	33,967	24,221
Exchange differences on translation in foreign operations	41	66
Unrealized (losses) gains on financial assets measured at fair value through other comprehensive income	(11,352)	84,142
Cash dividend distributed	(40,287)	(21,390)
Change in non-controlling interests	-	51,453
Changes in ownership interest in subsidiaries	111	23
Disposal of subsidiary	180	-
Balance at June 30	<u>\$ 743,152</u>	<u>703,317</u>

(p) Earnings per share

For the six months ended June 30, 2025 and 2024, the Company's earnings per share were calculated as follows:

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Basic earnings per share				
Profit attributable to ordinary shareholders of the Company	<u>\$ 284,656</u>	<u>261,711</u>	<u>675,752</u>	<u>542,482</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Weighted average number of ordinary shares	248,650	248,650	248,650	248,650
	<u>\$ 1.14</u>	<u>1.05</u>	<u>2.72</u>	<u>2.18</u>
Diluted earnings per share				
Profit attributable to ordinary shareholders of the Company (diluted)	<u>\$ 284,656</u>	<u>261,711</u>	<u>675,752</u>	<u>542,482</u>
Weighted average number of ordinary shares	248,650	248,650	248,650	248,650
Effect of employees' compensation	97	95	327	325
Weighted average number of ordinary shares (diluted)	<u>248,747</u>	<u>248,745</u>	<u>248,977</u>	<u>248,975</u>
	<u>\$ 1.14</u>	<u>1.05</u>	<u>2.71</u>	<u>2.18</u>

(q) Revenue from contracts with customers

(i) Disaggregation of revenue

For the three months ended June 30, 2025							
	Oncology Business Unit	Intensive Care Business Unit	HealthCare Business Unit	Export and CDMO Business Unit	Other Business Unit	Re-investment Business Unit	Total
Primary geographical markets:							
Taiwan	\$ 626,851	254,750	47,738	48,642	1,546	264,298	1,243,825
America	-	-	-	156,186	-	-	156,186
Other countries	-	-	-	108,363	-	3,676	112,039
	<u>\$ 626,851</u>	<u>254,750</u>	<u>47,738</u>	<u>313,191</u>	<u>1,546</u>	<u>267,974</u>	<u>1,512,050</u>
Major products/services lines:							
Medicine and functional food	\$ 623,851	254,750	47,730	256,859	-	254,128	1,437,318
Services	3,000	-	8	161	-	13,846	17,015
Royalty	-	-	-	56,171	1,546	-	57,717
	<u>\$ 626,851</u>	<u>254,750</u>	<u>47,738</u>	<u>313,191</u>	<u>1,546</u>	<u>267,974</u>	<u>1,512,050</u>
For the three months ended June 30, 2024							
	Oncology Business Unit	Intensive Care Business Unit	HealthCare Business Unit	Export and CDMO Business Unit	Other Business Unit	Re-investment Business Unit	Total
Primary geographical markets:							
Taiwan	\$ 589,708	255,787	46,253	52,584	-	234,625	1,178,957
America	-	-	-	80,293	32,345	-	112,638
Other countries	-	-	-	81,247	-	1,809	83,056
	<u>\$ 589,708</u>	<u>255,787</u>	<u>46,253</u>	<u>214,124</u>	<u>32,345</u>	<u>236,434</u>	<u>1,374,651</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

For the three months ended June 30, 2024							
	<u>Oncology Business Unit</u>	<u>Intensive Care Business Unit</u>	<u>HealthCare Business Unit</u>	<u>Export and CDMO Business Unit</u>	<u>Other Business Unit</u>	<u>Re-investment Business Unit</u>	<u>Total</u>
Major products/services lines:							
Medicine and functional food	\$ 589,708	255,787	45,901	186,100	-	226,156	1,303,652
Services	-	-	352	1,086	-	10,278	11,716
Royalty	-	-	-	26,938	32,345	-	59,283
	<u>\$ 589,708</u>	<u>255,787</u>	<u>46,253</u>	<u>214,124</u>	<u>32,345</u>	<u>236,434</u>	<u>1,374,651</u>
For the six months ended June 30, 2025							
	<u>Oncology Business Unit</u>	<u>Intensive Care Business Unit</u>	<u>HealthCare Business Unit</u>	<u>Export and CDMO Business Unit</u>	<u>Other Business Unit</u>	<u>Re-investment Business Unit</u>	<u>Total</u>
Primary geographical markets:							
Taiwan	\$ 1,191,651	534,021	93,364	103,778	1,546	544,623	2,468,983
America	-	-	-	277,592	-	-	277,592
Other countries	-	-	-	216,542	-	7,783	224,325
	<u>\$ 1,191,651</u>	<u>534,021</u>	<u>93,364</u>	<u>597,912</u>	<u>1,546</u>	<u>552,406</u>	<u>2,970,900</u>
Major products/services lines:							
Medicine and functional food	\$ 1,182,151	534,021	93,351	496,049	-	526,230	2,831,802
Services	9,500	-	13	1,126	-	26,176	36,815
Royalty / commission	-	-	-	100,737	1,546	-	102,283
	<u>\$ 1,191,651</u>	<u>534,021</u>	<u>93,364</u>	<u>597,912</u>	<u>1,546</u>	<u>552,406</u>	<u>2,970,900</u>
For the six months ended June 30, 2024							
	<u>Oncology Business Unit</u>	<u>Intensive Care Business Unit</u>	<u>HealthCare Business Unit</u>	<u>Export and CDMO Business Unit</u>	<u>Other Business Unit</u>	<u>Re-investment Business Unit</u>	<u>Total</u>
Primary geographical markets:							
Taiwan	\$ 1,123,340	521,210	92,396	103,979	-	431,705	2,272,630
America	-	-	-	134,181	32,345	-	166,526
Other countries	-	-	-	203,868	-	5,232	209,100
	<u>\$ 1,123,340</u>	<u>521,210</u>	<u>92,396</u>	<u>442,028</u>	<u>32,345</u>	<u>436,937</u>	<u>2,648,256</u>
Major products/services lines:							
Medicine and functional food	\$ 1,123,340	521,210	91,845	391,350	-	376,987	2,504,732
Services	-	-	551	1,461	-	59,950	61,962
Royalty / commission	-	-	-	49,217	32,345	-	81,562
	<u>\$ 1,123,340</u>	<u>521,210</u>	<u>92,396</u>	<u>442,028</u>	<u>32,345</u>	<u>436,937</u>	<u>2,648,256</u>

(ii) Contract balances

	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
Contract liability	<u>\$ 32,585</u>	<u>34,340</u>	<u>12,561</u>

For details on accounts receivable and allowance for expected credit losses, please refer to Note 6(c).

The amount of revenue recognized for the six months ended June 30, 2025 and 2024 that were included in the contract liability balance at the beginning of the period were \$16,709 thousand and \$7,071 thousand, respectively.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(r) Remunerations to employees and directors

On May 29, 2025, the Company resolved at the shareholders' meeting to amend its Articles of Incorporation. According to the amended Articles of Incorporation, if the Company has profit in a given year, 0.5% to 10% of the profit should be allocated as employee remuneration (with no less than 0.5% of the profit to be distributed to entry-level employees), and a maximum of 2% of the profit shall be allocated as remuneration to directors and supervisors. However, if the Company has accumulated losses, the Company shall reserve an amount to cover such losses in advance. Prior to the amendment, the Articles of Incorporation stipulated that, if the Company has profit in a given year, 0.5% to 10% should be allocated as employee remuneration and no more than 2% should be allocated as remuneration to the directors. However, if the Company has accumulated losses, the Company shall reserve an amount to cover such losses in advance.

For the three months ended June 30, 2025 and 2024 and the six months ended June 30, 2025 and 2024, the Company estimated its employee remuneration at \$7,303 thousand, \$7,209 thousand, \$14,607 thousand and \$14,417 thousand, respectively, and directors' remuneration at \$3,738 thousand, \$3,738 thousand, \$7,475 thousand and \$7,475 thousand, respectively. These amounts were calculated by using the Company's profit before tax for the period before deducting the amounts of the remuneration to employees and directors based on the Company's Articles of Incorporation and the amount was recognized under operating expenses. Related information would be available at the Market Observation Post System website. The amounts, as stated in the consolidated financial statements, are identical to those of the actual distributions for 2024 and 2023.

For the years ended December 31, 2024 and 2023, the Company accrued and recognized its employee compensation amounting to \$33,081 thousand and \$29,189 thousand, respectively and its remuneration to directors both amounting to \$15,600 thousand and \$14,950 thousand. The actual distribution and related information can be accessed from the website of Market Observation Post System.

(s) Non-operating income and expenses

(i) Interest income

The details of total interest income for the three months and six months ended June 30, 2025 and 2024 were as follows:

	For the three months ended		For the six months ended	
	June 30,		June 30,	
	2025	2024	2025	2024
Interest income from bank deposits	\$ <u>19,932</u>	<u>23,593</u>	<u>37,923</u>	<u>43,135</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Other income

The details of other income for the three months and six months ended June 30, 2025 and 2024 were as follows:

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Rent revenue	\$ 2,693	2,750	5,445	5,390
Compensation income	6	-	37,792	-
Others	57	306	180	306
	<u>\$ 2,756</u>	<u>3,056</u>	<u>\$ 43,417</u>	<u>5,696</u>

The Company reached an out-of-court settlement with Inopha AG on January 21, 2025, and recognized a litigation settlement gain. For further details regarding the related litigation, please refer to Note 12.

(iii) Other gains and losses

The details of other gains and losses for the three months and six months ended June 30, 2025 and 2024 were as follows:

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Gains (losses) on disposal of property, plant and equipment	\$ (19)	(112)	80	138
Gains on disposal of investments	-	-	946	-
Foreign exchange gains (losses)	(63,814)	6,629	(57,485)	16,391
Reversal of impairment losses of non-financial assets	-	-	-	2,000
Other	2,721	(5,871)	9,205	(5,561)
	<u>\$ (61,112)</u>	<u>646</u>	<u>(47,254)</u>	<u>12,968</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iv) Finance costs

The details of finance costs for the three months and six months ended June 30, 2025 and 2024 were as follows:

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Interest expense	\$ 10,016	9,984	18,190	17,298
Other finance costs	179	136	348	186
	<u>\$ 10,195</u>	<u>10,120</u>	<u>18,538</u>	<u>17,484</u>

(t) Financial instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For related information, please refer to Note 6(u) of the consolidated financial statements for the year ended December 31, 2024.

(i) Credit risk of receivables

Please refer to Note 6(c) for information of credit risk exposure of notes and accounts receivable.

All other financial assets measured at amortized cost include other receivables, time deposits, refundable deposit paid and other financial assets. All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected credit losses. With regards to how the financial instruments are considered to have low credit risk, please refer to Note 4(g) of the consolidated financial statements for the year ended December 31, 2024. Please refer to Note 6(j) for information of credit risk.

(ii) Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements.

	Carrying value	Contractual cash flows	Within 1 year	2-3 years	4-5 years
June 30, 2025					
Non-derivative financial liabilities					
Bank loans	\$ 2,200,000	2,209,657	2,108,706	100,951	-
Non-interest-bearing liabilities (including related parties)	868,256	868,256	868,256	-	-
Lease liabilities (current and non-current)	14,660	15,510	7,521	7,989	-
Guarantee deposits received	2,424	2,424	2,424	-	-
	<u>\$ 3,085,340</u>	<u>3,095,847</u>	<u>2,986,907</u>	<u>108,940</u>	<u>-</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	<u>Carrying value</u>	<u>Contractual cash flows</u>	<u>Within 1 year</u>	<u>2-3 years</u>	<u>4-5 years</u>
December 31, 2024					
Non-derivative financial liabilities					
Bank loans	\$ 1,700,000	1,712,409	1,610,402	102,007	-
Non-interest-bearing liabilities (including related parties)	975,297	975,297	975,297	-	-
Lease liabilities (current and non-current)	11,129	11,811	6,195	5,378	238
Guarantee deposits received	<u>2,440</u>	<u>2,440</u>	<u>2,440</u>	<u>-</u>	<u>-</u>
	\$ <u>2,688,866</u>	<u>2,701,957</u>	<u>2,594,334</u>	<u>107,385</u>	<u>238</u>
June 30, 2024					
Non-derivative financial liabilities					
Bank loans	\$ 2,400,000	2,415,754	2,014,302	401,452	-
Non-interest-bearing liabilities (including related parties)	768,842	768,842	763,042	5,800	-
Lease liabilities (current and non-current)	8,820	8,936	6,814	2,122	-
Guarantee deposits received	<u>2,438</u>	<u>2,438</u>	<u>2,438</u>	<u>-</u>	<u>-</u>
	\$ <u>3,180,100</u>	<u>3,195,970</u>	<u>2,786,596</u>	<u>409,374</u>	<u>-</u>

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amounts.

(iii) Market risk

1) Currency risk

The Group's significant exposure of financial assets and liabilities to foreign currency risk was as follows:

	June 30, 2025				December 31, 2024			June 30, 2024		
	Foreign Currency	Exchange Rate		NTD	Foreign Currency	Exchange Rate	NTD	Foreign Currency	Exchange Rate	NTD
Financial assets										
Monetary items										
USD	\$	19,895	29.3000	582,937	18,009	32.7850	590,428	12,830	32.4500	416,319
JPY		79,157	0.2034	16,101	96,379	0.2099	20,230	150,255	0.2017	30,306
EUR		1,299	34.3500	44,625	124	34.1400	4,244	14	34.7100	479
Non-monetary items										
USD		44,143	29.3000	1,293,386	43,651	32.7850	1,431,102	51,112	32.4500	1,658,589
CNY		29,814	4.0910	121,969	30,775	4.4780	137,810	30,372	4.4450	135,003
THB		454,720	0.9069	439,592	461,687	0.9623	444,281	439,906	0.8867	390,065

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	June 30, 2025			December 31, 2024			June 30, 2024		
	Foreign Currency	Exchange Rate	NTD	Foreign Currency	Exchange Rate	NTD	Foreign Currency	Exchange Rate	NTD
<u>Financial liabilities</u>									
<u>Monetary items</u>									
USD	224	29.3000	6,569	1,532	32.7850	50,233	1,936	32.4500	62,819
JPY	15,759	0.2034	3,205	15,759	0.2099	3,308	20,828	0.2017	4,201
PHP	1,482	34.3500	50,899	-	-	-	-	-	-

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents and accounts receivable that are denominated in foreign currency. Net investments in a foreign operation are strategic investments, so the Group does not treat them as a hedge.

For the six months ended June 30, 2025 and 2024, a strengthening (weakening) of 1% of the NTD against the USD, CNY, JPY and EUR as of would have (decreased) increased the net profit after tax by \$4,664 thousand and \$3,041 thousand, respectively. The analysis is performed on the same basis for both periods.

Since the Group has many kinds of functional currency, the information on foreign exchange gains (losses) on monetary items is disclosed by total amount. For the six months ended June 30, 2025 and 2024, the foreign exchange gains (including realized and unrealized portions) amounted gains \$57,485 thousand and gains \$16,391 thousand, respectively.

2) Interest rate analysis

The exposure to interest rate risk on financial assets and liabilities is disclosed in the note on liquidity risk management.

The Group mainly borrows capital at floating interest rates, so the cash flow risk arises from changes in interest rates. The Group's main source of borrowed capital is bank loans.

Regarding the liabilities with variable interest rates, their sensitivity analysis is based on the assumption that the amount of liabilities outstanding at the reporting date was outstanding throughout the year. The fluctuation rate is expressed as the interest rate increases or decreases by 0.25%, which also represents the Group management's assessment of the reasonably possible interest rate change, when reporting to the internal management.

If the interest rate had increased/decreased by 0.25%, the Group's after-tax net income would have decreased/increased by \$980 thousand and \$1,677 thousand for the six months ended June 30, 2025 and 2024, respectively with all other variable factors remaining constant.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

3) Other market price risk

For the six months ended June 30, 2025 and 2024, the sensitivity analyses for the changes in the securities price at the reporting date were performed using the same basis for profit or loss as illustrated below:

	For the six months ended June 30,			
	2025		2024	
	Other Comprehensive income after tax	Net income	Other Comprehensive income after tax	Net income
Prices of securities at the reporting date				
Increasing 10%	\$ 24,913	-	46,704	-
Decreasing 10%	\$ (24,913)	-	(46,704)	-

(iv) Fair value of financial instruments

1) Categories and fair value of financial instruments

The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy, were as follows; However, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and for lease liabilities, disclosure of fair value information is not required:

	June 30, 2025				
	Carrying Value	Fair Value			
		Level 1	Level 2	Level 3	Total
Financial assets at fair value through other comprehensive income					
Domestic stock in listed company at Stock Exchange	\$ 181,532	181,532	-	-	181,532
Domestic stock in listed company at Taipei Exchange	45,131	45,131	-	-	45,131
Domestic unlisted stock	11,992	-	-	11,992	11,992
International stock	10,479	-	-	10,479	10,479
Subtotal	249,134	226,663	-	22,471	249,134
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 2,555,791	-	-	-	-
Notes and accounts receivable (including related party)	1,277,048	-	-	-	-
Other receivables (including related party)	176,130	-	-	-	-
Other financial assets (current and non-current)	508,695	-	-	-	-
Refundable deposits paid	30,451	-	-	-	-
Subtotal	4,548,115	-	-	-	-
Total	\$ 4,797,249	226,663	-	22,471	249,134

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

June 30, 2025					
	Carrying Value	Fair Value			
		Level 1	Level 2	Level 3	Total
Financial liabilities measured at amortized cost					
Bank loans	\$ 2,200,000	-	-	-	-
Notes and accounts payable (including related party)	245,095	-	-	-	-
Dividends payable	40,287	-	-	-	-
Other payables (including related party)	582,874	-	-	-	-
Lease liabilities (current and non-current)	14,660	-	-	-	-
Guarantee deposit received	2,424	-	-	-	-
Total	<u><u>\$ 3,085,340</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>
December 31, 2024					
	Carrying Value	Fair Value			
		Level 1	Level 2	Level 3	Total
Financial assets at fair value through other comprehensive income					
Domestic stock in listed company at Stock Exchange	\$ 175,734	175,734	-	-	175,734
Domestic stock in listed company at Taipei Exchange	77,015	77,015	-	-	77,015
Domestic unlisted stock	11,992	-	-	11,992	11,992
International stock	10,479	-	-	10,479	10,479
Subtotal	<u>275,220</u>	<u>252,749</u>	<u>-</u>	<u>22,471</u>	<u>275,220</u>
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 2,772,615	-	-	-	-
Notes receivable and accounts receivable (including related party)	1,353,672	-	-	-	-
Other receivables (including related party)	23,181	-	-	-	-
Other financial assets (current and non-current)	408,817	-	-	-	-
Refundable deposits paid	30,463	-	-	-	-
Subtotal	<u>4,588,748</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u><u>\$ 4,863,968</u></u>	<u><u>252,749</u></u>	<u><u>-</u></u>	<u><u>22,471</u></u>	<u><u>275,220</u></u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

December 31, 2024					
	Carrying Value	Fair Value			
		Level 1	Level 2	Level 3	Total
Financial liabilities measured at amortized cost					
Bank loans	\$ 1,700,000	-	-	-	-
Notes payable and accounts payable (including related party)	326,158	-	-	-	-
Other payables (including related party)	649,139	-	-	-	-
Lease liabilities (current and non- current)	11,129	-	-	-	-
Guarantee deposit received	2,440	-	-	-	-
Total	<u><u>\$ 2,688,866</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>
June 30, 2024					
	Carrying Value	Fair Value			
		Level 1	Level 2	Level 3	Total
Financial assets at fair value through other comprehensive income					
Domestic stock in listed company at Stock Exchange	\$ 173,427	173,427	-	-	173,427
Domestic stock in listed company at Taipei Exchange	272,600	272,600	-	-	272,600
Domestic unlisted stock	11,992	-	-	11,992	11,992
International stock	9,017	-	-	9,017	9,017
Subtotal	<u>467,036</u>	<u>446,027</u>	<u>-</u>	<u>21,009</u>	<u>467,036</u>
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 2,573,789	-	-	-	-
Notes and accounts receivable (including related party)	1,283,585	-	-	-	-
Other receivables (including related party)	66,878	-	-	-	-
Other financial assets (current and non-current)	304,064	-	-	-	-
Refundable deposits paid	34,250	-	-	-	-
Subtotal	<u>4,262,566</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u><u>\$ 4,729,602</u></u>	<u><u>446,027</u></u>	<u><u>-</u></u>	<u><u>21,009</u></u>	<u><u>467,036</u></u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	June 30, 2024				
	Carrying Value	Fair Value			
		Level 1	Level 2	Level 3	Total
Financial liabilities measured at amortized cost					
Bank loans	\$ 2,400,000	-	-	-	-
Notes and accounts payable (including related party)	207,794	-	-	-	-
Dividends payable	21,390	-	-	-	-
Other payables (including related party)	533,858	-	-	-	-
Lease liabilities (current and non-current)	8,820	-	-	-	-
Guarantee deposit received	2,438	-	-	-	-
Other non-current liabilities	<u>5,800</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 3,180,100</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

2) Fair value hierarchy

The Group analyzes financial instruments carried at fair value by the levels in the fair value hierarchy. The different levels have been defined as follows:

- a) Level 1: quoted prices (unadjusted) in active markets for identified assets or liabilities.
- b) Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

3) Valuation techniques for financial instruments not measured at fair value

The Group's valuation techniques and assumptions used for financial instruments not measured at fair value are as follows:

The financial instrument mentioned above is either close to its expiry date, or their future receivable or payable is close to its carrying value; thus, its fair value is estimated from the book value of the balance sheet date.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

4) Valuation techniques for financial instruments measured at fair value

Non-derivative financial instruments

The fair value of financial instruments traded in an active market is based on the quoted market prices. The quotations, which are published by the main exchange center or that which was deemed to be a public bond by the Treasury Bureau of Central Bank, are included in the fair value of the listed securities instruments and the debt instruments in active market with open bid.

A financial instrument is regarded as being quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's-length basis. Whether transactions are taking place 'regularly' is a matter of judgment and depends on the facts and circumstances of the market for the instrument.

Quoted market prices may not be indicative of the fair value of an instrument if the activity in the market is infrequent, the market is not well-established, only small volumes are traded, or bid-ask spreads are very wide. Determining whether a market is active involves judgment.

For financial instruments traded in active markets under standard terms and conditions, their fair values are based on quoted market prices.

For financial instruments not traded in active markets, their fair values are listed below by types and attributes:

- Equity instruments without a public quotation: The fair value is estimated based on the transaction prices of the stocks of the companies engaged in the same or similar business in the active market. The value multipliers implied by these prices and relevant transaction information determine the value of the evaluated companies and the liquidity discount is taken into consideration.

The fair value of financial instruments traded in active markets is based on quoted market prices.

5) Transfer between levels

There was no change in valuation techniques for financial instruments measured at fair value for the six months ended June 30, 2025 and 2024, so there was no transfer between levels.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

6) Reconciliation of Level 3 fair values

	Fair value through other comprehensive income
	Unquoted equity instruments
Balance at January 1, 2025	\$ 22,471
Balance at June 30, 2025	\$ 22,471
Balance at January 1, 2024	\$ 21,009
Balance at June 30, 2024	\$ 21,009

7) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include "fair value through other comprehensive income – equity investments".

Most of the Group's financial instruments that use Level 3 inputs have only one significant unobservable input. Only equity investments without an active market have multiple significant unobservable input.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
Financial assets measured at fair value through other comprehensive income - equity investments without an active market	Comparable companies method	Discount for lack of market liquidity (On June 30, 2025, December 31, 2024 and June 30, 2024 all of 27.3%~30%)	The higher the discount for lack of market liquidity, the lower the fair value.

8) Fair value measurements in Level 3 – sensitivity analysis of reasonably possible alternative assumptions

The valuation models and assumptions used to measure the fair value of financial instruments are reasonable. However, the use of different valuation models or assumptions may result in different measurements. The following is the effect of other comprehensive income from financial assets and liabilities categorized within Level 3 if the inputs used in valuation models have changed:

	Input	Change	Other comprehensive income	
			Favorable	Unfavorable
June 30, 2025				
Financial assets at fair value through other comprehensive income - equity investments without an active market	Discounted of liquidity	1%	270	(270)

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

			Other comprehensive income	
	Input	Change	Favorable	Unfavorable
December 31, 2024				
Financial assets at fair value through other comprehensive income - equity investments without an active market	Discounted of liquidity	1%	270	(270)
June 30, 2024				
Financial assets at fair value through other comprehensive income - equity investments without an active market	Discounted of liquidity	1%	255	(255)

The favorable and unfavorable effects represent the changes in fair value, which is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the interrelationships with another input.

(u) Financial risk management

There were no significant changes in the Group's financial risk management and policies as disclosed in Note 6(v) of the consolidated financial statements for the year ended December 31, 2024.

(v) Capital management

Management believes that the objectives, policies and processes of capital management of the Group has been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2024. Also, there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2024. Please refer to Note 6(w) of the consolidated financial statements for the year ended December 31, 2024 for further details.

(7) Related-party transactions:

(a) Names of related parties and relationship

The followings are entities that have had transactions with related party during the periods covered in the consolidated financial statements.

<u>Name of related party</u>	<u>Relationship with the Group</u>
American Taiwan Biopharm (ATB)	An associate
PharmaEngine, Inc.	An associate

(b) Significant transactions with related parties

(i) Sales revenue

The amounts of significant sales by the Group to related parties were as follows:

	<u>For the three months ended</u>		<u>For the six months ended</u>	
	<u>June 30,</u>	<u>June 30,</u>	<u>June 30,</u>	<u>June 30,</u>
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Associates	<u>\$ 45,196</u>	<u>22,581</u>	<u>78,032</u>	<u>58,544</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The selling prices with associates were marked up by 100% of the cost of goods sold. If the collection was past due three months, then 5% interest was charged.

(ii) Service revenue

The Group's service revenue for related party was as follows:

<u>Recognized item</u>	<u>Category</u>	<u>For the three months ended June 30</u>		<u>For the six months ended June 30</u>	
		<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Service revenue	Associate	\$ <u>-</u>	<u>-</u>	<u>331</u>	<u>-</u>

(iii) Other gains

The amounts of other gains by the Group from related parties were as follows:

<u>Recognized item</u>	<u>Category</u>	<u>For the three months ended June 30,</u>		<u>For the six months ended June 30,</u>	
		<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Other gains	Associate-ATB	\$ <u>3,252</u>	<u>3,039</u>	<u>6,626</u>	<u>6,247</u>

Other gains of the Group to the associates were mainly paid in accordance with the management service contract between the two parties. The payment terms are three months.

(c) Assets and liabilities with related parties

<u>Recognized item</u>	<u>Category</u>	<u>June 30, 2025</u>	<u>December 31, 2024</u>	<u>June 30, 2024</u>
Accounts receivable	Associates	\$ <u>46,043</u>	<u>7,385</u>	<u>22,677</u>
Other receivables	Associate-ATB	\$ 4,166	4,082	3,832
	Associate-PharmaEngine, Inc.	155,146	-	38,800
		\$ <u>159,312</u>	<u>4,082</u>	<u>42,632</u>

The information about the expected credit losses for notes receivable and accounts receivable, please refer to Note 6(c).

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(d) Key management personnel compensation

Key management personnel compensation comprised:

	For the three months ended June 30,		For the six months ended June 30,	
	2025	2024	2025	2024
Salaries and other short-term employee benefits	\$ 18,554	15,092	39,923	37,108
Post-employment benefits	344	313	707	608
	<u>\$ 18,898</u>	<u>15,405</u>	<u>40,630</u>	<u>37,716</u>

(8) Assets pledged as security:

The carrying amounts of pledged assets were as follows:

Pledged asset	Object	June 30, 2025	December 31, 2024	June 30, 2024
Other financial assets- non-current	Guarantee for provision attachment	\$ 149,380	149,380	149,380
Other financial assets- non-current	Account receivable from distributors	5,000	5,000	-
		<u>\$ 154,380</u>	<u>154,380</u>	<u>149,380</u>

(9) Significant commitments and contingencies:

- (a) The Group's unfinished contracts as of June 30, 2025, December 31, 2024 and June 30, 2024 were as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Total price of unfinished contracts			
Purchase of equipment and construction engineering	<u>\$ 162,851</u>	<u>120,467</u>	<u>54,381</u>
Acquisition of intangible assets	<u>\$ 355,984</u>	<u>437,700</u>	<u>407,668</u>
Research and development service	<u>\$ 86,000</u>	<u>91,115</u>	<u>89,264</u>
Purchase of raw materials	<u>\$ 105,799</u>	<u>109,066</u>	<u>109,647</u>
Unpaid amount			
Purchase of equipment and construction engineering	<u>\$ 118,869</u>	<u>88,445</u>	<u>20,592</u>
Acquisition of intangible assets	<u>\$ 275,489</u>	<u>338,928</u>	<u>330,030</u>
Research and development service	<u>\$ 18,587</u>	<u>19,099</u>	<u>21,985</u>
Purchase of raw materials	<u>\$ 27,469</u>	<u>30,736</u>	<u>30,422</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (b) As of June 30, 2025, December 31, 2024, and June 30, 2024, the financial institutions provided guarantee for the import and sale of medicine amounted to \$56,875 thousand, \$35,015 thousand and \$47,395 thousand, respectively.
- (c) On May 8, 2017, the Group signed a joint venture contract with 2-BBB MEDICINES BV (2-BBB) to jointly establish EnhanceX. However, a dispute arose between the two parties, wherein 2-BBB claimed that the Group has breached the contract. Subsequently, on May 28, 2025, the parties reached a settlement agreement, under which the Group agreed to compensate 2-BBB in the amount of \$18,000 thousand. A settlement agreement was signed, and the related matters will be completed in accordance with the terms of the agreement.
- (d) After being notified of certain improper activities of Huan-Lei Biotechnology Ltd. (“Huan-Lei”), the Company’s distribution partner, the Company voluntarily informed the Criminal Investigation Bureau (CIB) about the matter for further investigation. During the investigation, Taiwan Shilin District Prosecutors Office found that TTY’s payments totaling \$53,900 thousand to third parties, made out of Huan-Lei’s request, should be considered Huan-Lei’s illegal gains and therefore issued a letter to the Company on December 25, 2023, requesting return of said illegal gains. After consultation with external lawyers explaining about the complexity of the dispute that has yet to be tried, the Company evaluated the probability of filing claims for return of the sum, claims against wrongdoers and relief, and set aside a reserve for the partial loss. On April 18, 2024, Taiwan Shilin District Prosecutors Office charged Shih, Chun Liang and other parties who are involved in the case. This case is currently under trial at Taiwan Shilin District Court.

(10) Losses due to major disasters: None

(11) Subsequent events: None

(12) Other:

- (a) A summary of current-period employee benefits, depreciation and amortization expenses, by function, was as follows:

By item	By function		For the three months ended June 30,			
			2025		2024	
	Operating Cost	Operating expense	Total	Operating Cost	Operating expense	Total
Employee benefit						
Salary	\$ 66,402	192,770	259,172	63,734	197,209	260,943
Health and labor insurance	6,888	14,082	20,970	6,504	13,529	20,033
Pension	3,617	7,999	11,616	3,561	7,866	11,427
Others	3,533	21,124	24,657	3,392	19,751	23,143
Depreciation expense	32,325	7,220	39,545	29,877	9,224	39,101
Amortization expense	7,736	5,901	13,637	309	4,828	5,137

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

By item	For the six months ended June 30,					
	2025			2024		
	Operating Cost	Operating expense	Total	Operating Cost	Operating expense	Total
Employee benefit						
Salary	\$ 129,940	378,971	508,911	124,394	367,671	492,065
Health and labor insurance	13,067	27,559	40,626	12,123	26,520	38,643
Pension	7,019	15,916	22,935	6,798	15,136	21,934
Others	7,215	43,251	50,466	5,812	33,717	39,529
Depreciation expense	64,436	14,261	78,697	59,487	16,734	76,221
Amortization expense	8,094	10,907	19,001	7,084	9,983	17,067

(b) Seasonality of operations:

The Group's operations are not affected by seasonal factors or cyclical factors.

- (c) The Group donated \$81,804 thousand and \$115,222 thousand to related medical foundations and associations to support non-profit organizations developing drugs and promoting disease prevention and correct dosage for the six months ended June 30, 2025 and 2024, respectively.
- (d) With regards to the dispute on the Risperidone Development Contract entered into between the Company and Center Laboratories, Inc. (referred to as CLI), the Company considered that the signing of the said contract did not comply with the relevant procedures and legal requirements and should therefore be deemed invalid. However, CLI disagreed with the Company's viewpoint and filed a civil lawsuit against the Company in the Taipei District Court on July 1, 2016, seeking a declaratory judgment of the said contract. After multiple trials and remands, on December 24, 2024, the Taiwan High Court ruled to dismiss our company's appeal, confirming the existence of the contractual relationship between the two parties. The Company has filed an appeal with the Supreme Court within the statutory period to protect the Company's legal rights.
- (e) On May 14, 2021, the Company was penalized by the Fair Trade Commission for concerted action due to the agreement it entered into with Lotus Pharmaceutical Co., Ltd. on February 4, 2009, regarding the exclusive right to sell “Furil Capsules”. On July 12, 2021, the Company filed a complaint with the Taipei High Administrative Court to revoke the above penalty. The case is being heard by the Taipei High Administrative Court.
- (f) On May 31, 2016, the Company filed a claim against Inopha AG (Inopha) in the Cantonal Court of Zug, Switzerland, requesting that all 13 license agreements between the Company and Inopha be declared null and void, and further requesting that Inopha return all benefits received from the 13 license agreements. On January 21, 2025, the Company reached an out of court settlement with Inopha AG and its beneficial owner Mr. Denis Opitz, and formally signed a settlement agreement. Both parties agreed to withdraw all related legal proceedings against each other to the extent permitted by law. The contract amount of EUR 21,456 thousand, which had been held in a trust account due to the aforementioned dispute, will be allocated in accordance with the settlement agreement, with approximately 65% allocated to the Company. More than half of the settlement amount allocated to the Company will be reserved for litigation expenses and other anticipated costs. The case was dismissed by the Cantonal Court of Zug on January 22, 2025.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (g) On May 30, 2016, Janssen Pharmaceutica NV (Janssen) filed a request for arbitration with the WIPO Arbitration and Mediation Center, at the Company's request, to confirm whether the monies incurred from the agreement in dispute belong to the Company or Inopha. The Company reached an out-of-court settlement with Inopha AG and its beneficial owner Mr. Denis Opitz on January 21, 2025, and formally signed a settlement agreement. Upon submission of a termination declaration by Janssen to WIPO, the arbitration will be dismissed by WIPO in accordance with Janssen's request and the aforementioned settlement agreement.
- (h) On February 28, 2020, the Company filed a civil lawsuit to the Labor Court Dresden of Germany against Denis Optiz, the beneficiary owner of Inopha AG. On January 21, 2025, the Company reached an out of court settlement with Inopha AG and its beneficial owner Mr. Denis Opitz and formally signed a settlement agreement. The case was dismissed by the Dresden Labor Court in February 2025.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(13) Other disclosures:

(a) Information on significant transactions:

The following is the information on the Group significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the six months ended June 30, 2025:

(i) Loans to other parties:

(In Thousands)

Number	Name of lender	Name of borrower	Account name	Related party	Highest balance of financing to other parties during the period (Note 4)	Ending balance (Note 5)	Actual usage amount during the period	Range of interest rates during the period	Purposes of fund financing for the borrower (Note 1)	Transaction amount for business between two parties	Reasons for short-term financing	Allowance for bad debt	Collateral		Individual funding loan limits (Note 2)	Maximum limit of fund financing (Note 3)
													Item	Value		
1	Xudong Haipu International Co., Ltd.	TTY Biopharm Korea Co., Ltd.	Receivables from related parties	Yes	8,790 USD 300	8,790 USD 300	8,790 USD 300	2.5%	2	-	Operating capital	-	-	-	1,179,233 USD 40,247	1,179,233 USD 40,247

The exchange rate of USD to NTD as of the reporting date is 1:29.30.

Note 1): Nature of financing activities is as follows:

- 1.Trading partner, the number is “1”.
- 2.Short-term financing, the number is “2”.

Note 2): The total amount for lending to a company shall not exceed 20% and 40% of the worth of the Company and its subsidiaries, respectively, in their latest financial statements. 100% directly and indirectly owned foreign subsidiaries are not subject to such limitation.

Note 3): The total amount available for lending purposes shall not exceed 20% and 40% of the worth of the Company and its subsidiaries, respectively, in their latest financial statements. 100% directly and indirectly owned foreign subsidiaries are not subject to such limitation.

Note 4): The highest balance of financing to other parties as of June 30, 2025.

Note 5): The amounts were approved by the Board of Directors.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Note 6): The amounts in foreign currencies were translated based on the spot exchange rate at the reporting date.

(ii) Guarantees and endorsements for other parties: None

(iii) Securities held as of June 30, 2025 (excluding investment in subsidiaries, associates and joint ventures):

(In Thousands of New Taiwan Dollar)

Name of holder	Category and name of security	Relationship with company	Account title	Ending balance				Note
				Shares/Units (thousands)	Carrying value	Percentage of ownership (%)	Fair value	
The Company	ExoOne Bio. Co., Ltd. Common Stock	-	Financial assets measured at fair value through other comprehensive income–non-current	700	11,992	2.46 %	11,992	
TSH Biopharm Co., Ltd.	Lumosa Therapeutics Co., Ltd. Common Stock	-	Financial assets measured at fair value through other comprehensive income– current	308	45,131	0.18 %	45,131	
"	Fubon Financial Holding Co., Ltd. Preferred Shares B	-	Financial assets measured at fair value through other comprehensive income–non-current	2,500	156,500	0.38 %	156,500	
"	Union Bank of Taiwan Preferred Shares A	-	"	400	21,960	0.20 %	21,960	
"	Fubon Financial Holding Co., Ltd. Preferred Shares C	-	"	58	3,072	0.02 %	3,072	
"	CellMax Ltd. Common Stock	-	"	1,593	10,479	- %	10,479	

(iv) Information regarding related-parties purchases and/or sales exceeding NT\$100 million or 20% of the Company's paid-in capital: None

(v) Information regarding receivables from related-parties exceeding NT\$100 million or 20% of the Company's paid-in capital: None

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(vi) Significant transactions and business relationship between the parent company and its subsidiaries:

(In Thousands of New Taiwan Dollars)

No.	Name of company	Name of counter-party	Nature of relationship	Intercompany transactions			
				Account name	Amount	Trading terms	Percentage of the consolidated net revenue or total assets
0	The Company	Worldco International Co., Ltd.	1	Royalty revenue	24,824	By contract	0.84%
0	The Company	TSH Biopharm Co., Ltd.	1	Sales revenue	44,327	"	1.49%
0	"	"	1	Commission expense	1,907	"	0.06%
0	"	"	1	Other income	2,449	"	0.08%
0	"	"	1	Other gains and losses	2,404	"	0.08%
0	"	"	1	Accounts receivable	4,945	"	0.05%
0	"	"	1	Other receivables	47,821	"	0.45%
0	"	American Taiwan Biopharma Phils Inc.	1	Sales revenue	2,293	"	0.08%
0	"	"	1	Accounts receivable	5,066	"	0.05%
0	"	"	1	Other receivables	4,926	"	0.05%
0	"	Chuang Yi Biotech Co., Ltd.	1	Sales revenue	54,183	"	1.82%
0	"	"	1	Commission expense	1,595	"	0.05%
0	"	"	1	Other gains and losses	3,171	"	0.11%
0	"	"	1	Accounts receivable	19,526	"	0.18%
1	TSH Biopharm Co., Ltd	TOP Pharm Medicalware Co., Ltd.	3	Sales revenue	41,747	"	1.41%
1	"	"	3	Accounts receivable	7,664	"	0.07%
1	"	"	3	Notes receivable	6,845	"	0.06%
1	"	"	3	Other receivables	5,111	"	0.05%

Note 1): The numbering is as follows:

1. "0" represents the parent company.
2. Subsidiaries are sequentially numbered from 1 by company.

Note 2): The types of transaction between the parent company and subsidiaries are as follows:

1. Transactions from parent company to subsidiary.
2. Transactions from subsidiary to parent company.
3. Transactions between subsidiaries.

Note 3): The transactions have been eliminated in the consolidated financial statements.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to Consolidated Financial Statements

Note 4): The related-party transactions less than NT\$1,000 thousand were not disclosed, and so were the relative transactions.

(b) Information on investees:

The following is the information on investees for the six months ended June 30, 2025 (excluding information on investees in Mainland China):

(In Thousands of New Taiwan Dollar)

Name of investor	Name of investee	Location	Main businesses and products	Original investment amount		Balance as of June 30, 2025			Net income (losses) of investee	Share of profits/losses of investee	Note
				June 30, 2025	December 31, 2024	Shares (thousands)	Percentage of ownership	Carrying value			
The Company	Xudong Haipu International Co., Ltd.	Cayman Is.	Investing activities	14,542	14,542	1,454	100.00 %	1,167,666	16,400	16,400	Subsidiary
The Company	Worldco International Co., Ltd.	Hong Kong	Selling chemical medicine	15,825	15,825	3,960	100.00 %	121,969	(2,300)	(2,300)	Subsidiary
The Company	American Taiwan Biopharma Philippines	Philippines	Selling chemical medicine	32,904	32,904	481	87.00 %	(4,468)	241	210	Subsidiary
The Company	TSH Biopharm Co., Ltd.	Taiwan	Selling chemical medicine	227,449	227,449	21,687	56.48 %	755,661	56,613	32,101	Subsidiary
The Company	EnhanX Biopharm Inc.	Taiwan	Developing chemical medicine	50,000	50,000	5,000	20.83 %	236	(1,009)	(210)	Subsidiary
The Company	Chuang Yi Biotech Co., Ltd.	Taiwan	Selling functional food	250,951	250,951	7,432	23.12 %	33,923	4,458	1,031	Subsidiary
The Company	PharmaEngine, Inc.	Taiwan	Developing chemical medicine	536,559	536,559	25,867	18.00 %	1,002,775	120,088	21,616	Investments accounted for using equity method
The Company	American Taiwan Biopharm	Thailand	Selling chemical medicine	2,966	2,966	380	40.00 %	439,592	83,760	33,504	Investments accounted for using equity method
The Company	Gligio International Limited	Hong Kong	Selling chemical medicine	2,685	2,685	620	40.00 %	125,720	49,998	19,999	Investments accounted for using equity method
Xudong Haipu International Co., Ltd.	EnhanX Biopharm Inc.	Taiwan	Developing chemical medicine	70,000	70,000	7,000	29.17 %	11,292	(1,009)	(294)	Subsidiary
Xudong Haipu International Co., Ltd.	TTY Biopharm Korea Co., Ltd.	Korea	Selling chemical medicine	59,404	59,404	449	100.00 %	7,793	(10,016)	(10,016)	Subsidiary
Xudong Haipu International Co., Ltd.	TTY Biopharm Mexico S.A. de C.V.	Mexico	Selling chemical medicine	26,638	26,638	17,500	50.00 %	-	-	-	Subsidiary
Worldco International Co., Ltd.	TTY Biopharm Mexico S.A. de C.V.	Mexico	Selling chemical medicine	26,638	26,638	17,500	50.00 %	-	-	-	Subsidiary
EnhanX Biopharm Inc.	EnhanX Biopharm B.V.	Netherlands	Developing chemical medicine	-	3,538	-	- %	-	-	-	Subsidiary
TSH Biopharm Co., Ltd.	Chuang Yi Biotech Co., Ltd.	Taiwan	Selling functional food	200,262	200,262	16,590	51.60 %	172,317	4,458	2,300	Subsidiary
TSH Biopharm Co., Ltd.	TOP Pharm Medicalware Co., Ltd.	Taiwan	Selling and manufacturing of medicine and functional food	301,451	257,121	2,529	51.00 %	324,967	17,506	8,928	Subsidiary

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to Consolidated Financial Statements

Name of investor	Name of investee	Location	Main businesses and products	Original investment amount		Balance as of June 30, 2025			Net income (losses) of investee	Share of profits/losses of investee	Note
				June 30, 2025	December 31, 2024	Shares (thousands)	Percentage of ownership	Carrying value			
TSH Biopharm Co., Ltd.	TOP Biological Technology Co., Ltd.	Taiwan	Food manufacturing	-	44,330	-	-	%	-	-	Note1
Chuang Yi Biotech Co., Ltd.	Immortal Fame Global Ltd.	Samoa	Import and export trading and investment activities	-	16,820	-	-	%	-	-	Note2

Note1): On January 1, 2025, TOP BT was merged with TOP PM in accordance with the Business Mergers and Acquisitions Act. Please refer to Note 4(b) for details.

Note2): Immortal Fame Global Ltd. was disposed of and the transaction was completed on January 6, 2025.

Note 3): The transaction was eliminated when preparing the consolidated financial statements.

(c) Information on investment in Mainland China:

(i) The names of investees in Mainland China, the main businesses and products, and other information:

(In Thousands)

Name of investee	Main businesses and products	Total amount of paid-in capital	Method of investment (Note 1)	Accumulated outflow of investment from Taiwan as of January 1, 2025	Investment flows		Accumulated outflow of investment from Taiwan as of June 30, 2025	Net income (losses) of the investee	Percentage of ownership	Investment income (losses) (Note 2)	Book value	Accumulated remittance of earnings in current period
					Outflow	Inflow						
Worldco Biotech Pharmaceutical Ltd. (Chengdu)	Selling chemical medicine	48,683	(2)	82,352	-	-	82,352	160	100 %	160	47,981	-
		CNY 11,900		CNY 20,130			CNY 20,130	CNY 36		CNY 36	CNY 11,728	

The exchange rate of USD to NTD as of the reporting date was 1:29.3000, and the average exchange rate of USD to NTD for the reporting period was 1:31.9413.

The exchange rate of CNY to NTD as of the reporting date was 1:4.0910, and the average exchange rate of CNY to NTD for the reporting period was 1:4.4063.

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Notes to Consolidated Financial Statements

Note 1): Investment methods are classified into the following four categories.

1. Remittance from third-region companies to invest in Mainland China.
2. Through the establishment of third-region companies, then investing in Mainland China.
3. Through transfer of investment to third-region existing companies, then investing in Mainland China.
4. Others.

Note 2): The amounts are presented in New Taiwan Dollar. Recognized investment gain (loss) and the carrying value of investment as of the reporting date in foreign currencies were translated based on the average exchange rate during the reporting period and the exchange rate at the reporting date, respectively.

(ii) Limitation on investment in Mainland China:

Accumulated Investment in Mainland China as of June 30, 2025	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment
NTD 82,352	NTD 1,383,780 (USD 47,228)	NTD 3,709,650

(iii) Significant transactions: None

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(14) Segment information:

(a) General information

The Group's operating segments required to be disclosed are categorized as Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Re-investment Business Unit, etc. The Group has other operating segments that are below the quantitative criteria located in the Logistics business Unit.

The segments' profit is measured at profit before tax. The Group assesses performance of the segments based on the segments' profit. The operating segments' accounting policies are similar to those described in Note 4 "significant accounting policies".

(b) Reportable segment profit or loss, segment assets, segment liabilities, and their measurement and reconciliations

The Group's operating segment information and reconciliation were as follows:

For the three months ended June 30, 2025	Oncology Business Unit	Intensive Care Business Unit	Healthcare Business Unit	Export and CDMO Business Unit	Other Business Unit	Re-investment Business Unit	Adjustment and elimination	Total
Revenue:								
Revenue from external customers	\$ 626,851	254,750	47,738	313,191	1,546	267,974	-	1,512,050
Intersegment revenues	24,824	-	18,596	20,171	-	24,319	(87,910)	-
Total revenue	<u>\$ 651,675</u>	<u>254,750</u>	<u>66,334</u>	<u>333,362</u>	<u>1,546</u>	<u>292,293</u>	<u>(87,910)</u>	<u>1,512,050</u>
Reportable segment profit or loss	<u>\$ 293,880</u>	<u>59,885</u>	<u>53,061</u>	<u>86,791</u>	<u>(134,327)</u>	<u>36,255</u>	<u>(1,914)</u>	<u>393,631</u>
For the three months ended June 30, 2024								
Revenue:								
Revenue from external customers	\$ 589,708	255,787	46,253	214,124	32,345	236,434	-	1,374,651
Intersegment revenues	20,321	-	22,207	21,411	-	39,141	(103,080)	-
Total revenue	<u>\$ 610,029</u>	<u>255,787</u>	<u>68,460</u>	<u>235,535</u>	<u>32,345</u>	<u>275,575</u>	<u>(103,080)</u>	<u>1,374,651</u>
Reportable segment profit or loss	<u>\$ 232,161</u>	<u>76,153</u>	<u>37,453</u>	<u>37,325</u>	<u>(48,059)</u>	<u>30,865</u>	<u>(16,381)</u>	<u>349,517</u>
For the six months ended June 30, 2025								
Revenue:								
Revenue from external customers	\$ 1,191,651	534,021	93,364	597,912	1,546	552,406	-	2,970,900
Intersegment revenues	24,824	23,193	30,990	46,630	-	46,362	(171,999)	-
Total revenue	<u>\$ 1,216,475</u>	<u>557,214</u>	<u>124,354</u>	<u>644,542</u>	<u>1,546</u>	<u>598,768</u>	<u>(171,999)</u>	<u>2,970,900</u>
Reportable segment profit or loss	<u>\$ 548,213</u>	<u>174,667</u>	<u>92,850</u>	<u>176,455</u>	<u>(143,698)</u>	<u>81,124</u>	<u>(20,384)</u>	<u>909,227</u>

(Continued)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

For the six months ended June 30, 2024	Oncology Business Unit	Intensive Care Business Unit	HealthCare Business Unit	Export and CDMO Business Unit	Other Business Unit	Re-investment Business Unit	Adjustment and elimination	Total
Revenue:								
Revenue from external customers	\$ 1,123,340	521,210	92,396	442,028	32,345	436,937	-	2,648,256
Intersegment revenues	20,321	563	40,792	41,839	-	40,290	(143,805)	-
Total revenue	<u>\$ 1,143,661</u>	<u>521,773</u>	<u>133,188</u>	<u>483,867</u>	<u>32,345</u>	<u>477,227</u>	<u>(143,805)</u>	<u>2,648,256</u>
Reportable segment profit or loss	<u>\$ 473,922</u>	<u>175,948</u>	<u>71,639</u>	<u>107,092</u>	<u>(149,873)</u>	<u>78,773</u>	<u>(39,931)</u>	<u>717,570</u>
Reportable segment assets								
Balance on June 30, 2025	<u>\$ 1,196,443</u>	<u>412,978</u>	<u>657,884</u>	<u>1,906,459</u>	<u>5,559,313</u>	<u>3,150,593</u>	<u>(2,213,405)</u>	<u>10,670,265</u>
Balance on December 31, 2024	<u>\$ 1,407,799</u>	<u>499,194</u>	<u>679,696</u>	<u>1,820,511</u>	<u>5,546,083</u>	<u>3,084,875</u>	<u>(2,175,392)</u>	<u>10,862,766</u>
Balance on June 30, 2024	<u>\$ 1,197,251</u>	<u>460,509</u>	<u>611,985</u>	<u>1,781,775</u>	<u>5,327,043</u>	<u>3,418,464</u>	<u>(2,547,147)</u>	<u>10,249,880</u>